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Coronary heart disease is in 1977 "the leading cause of death in nearly all
industrialised countries. The majority of deaths occur within 1 hour of the
onset of symptoms of a heart attack and the principal cause of death is ventricular
fibrillation.
The purpose of the work presented in this thesis is fourfold;
1. to review the literature on the relevance of cardiac arrhythmias to death from
coronary heart disease.
2. to assess the evidence that, following acute myocardial infarction, a
combination of local and systemic metabolic changes may increase the
frequency of cardiac arrhythmias.
3. to propose that in man, one of these changes, a rise in plasma concentration
of free fatty acids, can be reversed in the acute phase of myocardial infarction
by the administration of a nicotinic acid analogue.
4. to test by a controlled clinical trial the hypothesis that (a) such administration
would'reliably result in a lowering of free fatty acids concentrations 'and
(b) that this lowering of free fatty acids would result in a reduction in the
incidence of ventricular arrhythmias v
The results obtained from pilot studies and a double blind trial demonstrate
i) that free fatty acids can be lowered safely in man with acute myocardial
infarction.
ii) that where free fatty acids were successfully lowered within 5 hours of the
onset of symptoms of a heart attack, there was a reduction in the incidence of
ventricular arrhythmias.
This work is the only known clinical test of the hypothesis that raised plasma
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The purpose of this work is fourfold.
1. to review the literature on the relevance of cardiac arrhythmias
to death from coronary heart disease.
2. to assess the evidence that, following acute myocardial
infarction, a combination of local and systemic metabolic changes
may increase the frequency of cardiac arrhythmias.
3. to propose in man, that one of these changes, a rise in plasma
concentration of free fatty acids (FFA), can be reversed in the acute
phase of myocardial infarction by the administration of a nicotinic
acid analogue (NAA).
4. to test by a controlled clinical trial the hypothesis that a) such
administration would reliably result in a lowering of FFA
concentrations and b) that this lowering of FFA would result in a




The mechanism by which disease of the coronary arteries can
interrupt normal cardiac function and lead to sudden death has been
studied ever since William Harvey first described the function of
the coronary arteries in De Motu Cordis in 1628. ... aut ipsius
cordis caro, quae rectius per arteriam coronale nutritur."
Both Morgagni in De Seaibus (1761) and Heberden in his commentaries
on the history and cure of diseases (1802), related angina pectoris
'
to sudden death, while Alan Burns and Edward Jenner related angina
pectoris to pathological evidence of coronary artery disease. The
earliest recorded clinical and pathological diagnosis of coronary
artery occlusion as the cause of sudden death was made by
Adam Hammer writing in Wiener Medicinische Wochenschrift in
1878, and technical advance allowed Pardee, in 1920, to describe
changes in the electrocardiogram following coronary occlusion.
Only in the last fifteen years has there been any consistent
development in the knowledge of the systemic and local metabolic
responses to occlusion of the coronary arteries. The hypothesis
that there may be a causal relationship between one of these
metabolic abnormalities and the serious sequelae of a clinical heart
attack was published as recently as 1970 (Kurien and Oliver, 1970).
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The Problem of Sudden Death From
Coronary Heart Disease
Coronary heart disease (CHD) is, in 1977, the leading cause
of death in nearly all industrialised countries. In Britain as a whole,
the reported mortality from CHD has increased steadily since
1925, and the pattern of change in Scotland since 1950 is shown in
Figure 1.
Scotland has a particularly high incidence of CHD, and in 1972,
a total of 1858 episodes of suspected heart attack were recorded in
the city of Edinburgh alone. Of these, 999 were confirmed as
myocardial infarction (Armstrong et al, 1972). Within four weeks
of the onset of their symptoms of heart attack, 548 (55%) of these
persons were dead. The majority died in the first 24 hours of
illness, the median time of death being 1 hour 54 minutes from the
reported onset of symptoms suggestive of a heart attack. 50% of
the deaths occurred in the first hour of illness, and as a
consequence of the abrupt onset of the illness and its short duration,
61% were medically unattended between the onset of symptoms and
death. This experience has been confirmed in Ireland, Sweden and
U.S.A. (McNeilly and Pemberton, 1968; Wikland, 1971; Biork and
Wikland, 1972; Kuller and Fisher, 1966; Spiekerman et al, 1962)
and is reviewed by Prineas and Blackburn (1975).
Despite the introduction of coronary care units more than 50%
of patients dying from myocardial infarction still do so within 1
hour of the onset of their symptoms and without medical help even
in the most highly organised centres. It becomes apparent, there¬
fore, that new concepts of the management of myocardial infarction
are required.
The concept that death in patients with acute heart attacks can be
due to electrophysiological disorganisation as well as to the actual
loss of cardiac muscle bulk has been revealed by recent experiences




Figure 1. Percentage change in death rates from I.H.D. Scotland,
1950 - 1973. (Taken from Oliver, M.F., European
Symposium on Myocardial Infarction, 1976, Turnberry).
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It seems certain that early fatalities, including the majority of
sudden deaths, are predominantly due to disorganised ventricular
rhythms (Lawrie et al., 1967; Lown et al, 1967; Cobb et al, 1975;
Julian, 1976). Although atheroma of all three main coronary
arteries is found in some people dying of myocardial ischaemia,
evidence of complete coronary artery occlusion, and light
microscopic evidence of infarction, are often lacking in patients
who die suddenly (Spiekerman et al, 1962; Adelson and Hoffman,
1961; Cobb et al, 1975). Even the newer staining techniques reveal
areas of actual necrosis in no more than 50% of such patients. When
these lesions are found they are often insufficient in size to
compromise mechanical cardiac activity, and in patients rapidly
resuscitated from cardiac arrest evidence of myocardial infarction
may fail to develop. The subsequent life expectancy in these cases
may not differ from that for patients with proven infarction who did
not have catastrophic ventricular arrhythmias (Lawrie et al, 1967;
Geddes et al, 1967; Stannard and Sloman, 1969; McNamee et al,
1970).
Cardiac arrhythmias in patients without serious infarction may
thus be numerically important in the whole spectrum of death from
coronary heart disease. A reduction in their frequency by
therapeutic intervention might, therefore, make a valuable




Ventricular Arrhythmias in Coronary Heart Disease
Ectopic ventricular excitation is a common accompaniment of
coronary heart disease in both the asymptomatic and symptomatic
phases. Ectopic excitation produces extremely variable electro¬
cardiographic patterns, and can be either single ectopic discharges
from one or more foci, couplets and paroxysmal runs of ectopic
beats, or ventricular fibrillation. The ectopic rythms are often
paroxysmal in the individual, and not all types will necessarily
occur in one individual at any stage in the disease.
The variable patterns of the ventricular arrhythmias and their
paroxysmal occurrence, makes definition and quantitation of each
arrhythmia difficult, and the ventricular arrhythmias described in
the following review of published work, were inconsistently defined.
In the interpretation of the findings in the original studies in this
thesis the following conventions are used:-
Ventricular Premature Beats
Ventricular premature beats (VPB) include all isolated
ventricular contractions occurring as the result of premature
discharge from a focus in the ventricular wall. The only type of
VPB described separately is that in which the ECG shows the
initial deflection of the ectopic complex occurring before the end of
the T wave of the preceding beat irrespective of whether that beat
is sinus or ventricular in origin. This is described as the R upon T
phenomenon (Smirk, 1949; Smirk and Palmer, 1960). Further
refinements of this definition have been used by other authors, i.e.
R-R interval 85% of the preceding QT interval (Lown and Klein,
1969) and R occurring within 40 ms. of the apex of the T wave
(Vellani, 1972) have both been used to describe the R upon Apex T
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phenomenon. In the results section of this thesis the actual number
of R waves falling at any point upon a preceding T wave will be
given. The definition given by Vellani will then be applied to describe
any R wave falling upon the apex of a preceding T wave.
Ventricular Tachycardia
Ventricular tachycardia (VT) represents variable numbers of
consecutive VPB's occurring regularly or irregularly at rates from
70-200 or more per min. Within this description many arbitrary
definitions have been made and a comparative review of past studies
is, therefore, difficult. In the results section of this thesis VT is
defined as 4 or more consecutive VPB's occurring at an overall
rate of greater than 100 per min. (The same pattern of VPB's at
rates less than 100 per min. has been described as Accelerated
Indioventricular Rhythm. Because this rhythm has never been
considered to be associated with an excess mortality from
ventricular fibrillation, it is not described in the results section of
this thesis.) In addition to this arbitrary definition of VT the actual
R-R intervals between the consecutive VPB's which constitute VT
will be described.
Ventricular Fibrillation
Ventricular fibrillation (VF) is defined as totally disorganised
electrical activity of the myocardium and classified into Primary,
Complicating and Agonal as defined by Oliver et al (1967).
CHAPTER 1
Experimental Production of Ventricular Arrhythmias
Experimental work has attempted to reproduce, in animals, the
various arrhythmias recorded in man, and to relate these to the
occurrence of ventricular fibrillation in man. Large electrical
stimuli given to the surface of the ventricles during the inscription
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of the T wave (de Boer, 1920) produce a single VPB, or if the
stimulus is given during the so called Vulnerable Period can
produce VT or VF (Wiggers, 1940; Wiggers and Wegria, 1940; Moe,
1941). This finding prompted the hypothesis that although a single
VPB in man is in itself insufficient stimulus to produce VF,
multiple consecutive VPB's occurring during the vulnerable period
may have a cumulative effect such that the VF threshold is lowered
and a later single ectopic beat might then be able to initiate VF
(Wiggers et al, 1940; Wallace, 1968).
The type of VT induced in these experiments was rapid,
persistent and unifocal, and accompanied by falling blood pressure.
This is to be contrasted with the type of VT most commonly seen in
man with AMI which is often multifocal, usually of short duration'
and self terminating. The experimentally induced VT does, however,
resemble the VT of the vulnerable period which begins during the
inscription of the T wave as described in man with AMI (Lown, 1969;
Mogensen, 1970). This is-the usual commencement of VF where this
has been observed in man.
There is now much evidence that those factors which increase
the time taken to recover from the refractory state predispose to
VF (Han and Moe, 1964; Han et al, 1966). Coronary artery ligation
has been shown to increase the length of the vulnerable period but
does not significantly lower the energy threshold required to produce
VF. There is also evidence, in animals, that when coronary artery
ligation is carried out there are apparently two common patterns of
arrhythmias immediately preceding VF. Firstly a long train of
VPB's may occur with the last VPB falling on or near the preceding
T wave, i.e. in the vulnerable period of the preceding beat, and
followed abruptly by VF. The second pattern is a single VPB
triggering VT in the vulnerable period and this continues into VF.
Experimental evidence concerning the R upon T phenomenon
(Fastier and Smirk, 1948) in 80 Amarin treated animals, showed
that Amarin plus adrenaline always caused chaotic rhythm and that
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the R upon T phenomenon occurred in many experiments before
the onset of prolonged ventricular tachycardia (described as
ventricular flutter).
Occasionally an ectopic R wave was seen to fall on the apex
of the preceding T and then prolonged VT or ventricular flutter
ensued suddenly. These changes were recorded with surface
electrodes on the ventricle.
The authors of this work are careful to comment on the
objections to transferring information gained from the
consequences of direct heavy electrical stimulus of the animal
myocardium to the clinical situation in man.
The stimuli required were large but repeated lesser stimuli
did lower the VF threshold and when electrical stimulation
induced VT in the vulnerable period, the VF threshold diminished
to an energy level close to that expected from a single ectopic
discharge in man. As a consequence, the hypothesis exists that
VT of the vulnerable period or an ectopic R falling on the apex
of the preceding T wave could cause VF in man with myocardial
ischaemia.
SUMMARY
There is experimental evidence that direct electrical
stimulation of the animal myocardium can most readily induce
VF when applied during the so called vulnerable period which
normally lies within + 40 m. sec. of the apex of the T wave.




The Prognostic Significance of Ventricular Arrhythmias in the
Preclinical Phase of Coronary Heart Disease in Man
The prevalence of VPB's increases with age and parallels
the prevalence of Coronary Heart Disease (Hiss et al, 1960;
Chiang et al, 1970). The Tecumseh study of 3,642 persons
showed a higher incidence of manifest CHD in people with
VPB's on a single initial ECG, and the sudden death rate in
those with VPB's was three times that of the age adjusted
rate in those without VPB's. The Framingham study of 2,336
persons showed similar findings with reference to the initial
12 lead ECG. A major problem in these, and in most other
studies, is the length of time that the subjects could be monitored
for ventricular arrhythmias consistent with screening the
necessarily large populations. A standard 12 lead ECG as used
in Tecumseh and Framingham has a relatively short time scale
and usually reveals VPB's in approximately 8% of asymptomatic
people (Lown and Wolf, 1971), but continuous monitoring for 6
hours or more always increases the yield of arrhythmias (Hinkle,
1969). In the Hinkle study, the longer period of recording thus
detected more subjects with less frequent VPB's, who might be
expected to have a less serious prognosis than would be
associated with the presence of frequent VPB. The risk of
sudden death associated with the mere presence of any VPB's
was, therefore, probably initially overestimated. The risk of
sudden death in patients with any VPB's seems, however, to
remain independent of the other standard risk factors.
SUMMARY
Ventricular ectopic beats found on a routine ECG during
population screening constitute an added risk factor for sudden
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death independent of the standard risk factors for CHD. It seems
likely, however, that with larger numbers of subjects and longer
recordings with a consequently greater yield of VPB's, the mere
presence of ventricular arrhythmias will remain a relatively poor
discriminant factor in the prediction of sudden death in the individual.
CHAPTER 3
The Prognostic Significance of Ventricular Arrhythmias
During Acute Myocardial Infarction
As the consequence of the extensive experimental work in
animals, Smirk, in 1949, attempted to allocate prognostic
significance to the R upon T type of VPB in man. From a large
number of patients Smirk accummulated seventeen patients with R
upon T ectopics occurring as the result of various underlying
diseases of the myocardium. Six only of these were patients with
myocardial infarction.
The ectopic R wave was shown falling on either the preceding sinus
T wave (S/V type) or on a preceding ectopic T wave (V/V type).
Examples of each type of VPB are shown in Figure 2.
A retrospective review showed that of the six cases of myocard¬
ial infarction, five had S/V ectopics of whom two died suddenly.
Two patients had V/V ectopics of whom one died suddenly. Three
had runs of two or more ectopics and one died suddenly. The study
was interpreted as showing that the R upon T phenomenon was
uncommon in AMI and that, although the evidence was insufficient,
it was possible that the R upon T phenomenon had prognostic import.
A follow up paper by Smirk and Palmer (1960) described a further
eighty patients collected because they demonstrated the R upon T
phenomenon of some form. In this group only eighteen had acute
myocardial infarction. R upon T of the S/V form occurred in 82%
of all eighteen ECG's, and the V/V form in only 28%. It was plain,
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Figure 2. Examples of T wavelnterruptionRecorded During the work
of this Thesis and Classified According to Smirk and
Palmer 1960.
13
therefore, that the V/V form was an uncommon phenomenon on the
routine ECG. Of the eighteen patients with AMI fifteen died in a
mean period of 3.7 months after any R upon T was noted, and eight
died suddenly. The proportions of these eight who had either S/V
or V/V forms is not, however, revealed in the paper. Smirk and
Palmer's interpretation of the data based on their previous
experimental experience was that any form of T wave interruption
by an R wave probably indicates an added danger to the patient.
Quite apart from the small numbers involved in the original
studies the authors gave no comprehensive data on the risks of
sudden death in patients with AMI treated in the same hospitals,
and with either no evidence of arrhythmias or of arrhythmia of a
different type. Relative risks cannot, therefore, be calculated.
Prospective studies of a cohort of patients whose ECG's are
uniformly read can give estimates of the risk of death associated
with each type of arrhythmia and an early study of this type in
patients with AMI was that of Julian et al in 1964. One hundred
patients with AMI were studied within 48 hours from the onset of
symptoms. Thirty-one deaths occurred, twenty with preceding
major ventricular arrhythmias. Ventricular Tachycardia and
Ventricular Fibrillation were more common in the younger patients
and during the first 24 hours of the study. The higher mortality with
respect to VPB's was in the group with frequent VPB's when
compared with those with infrequent VPB's. The mortality in the
patients without VPB's, however, was similar to that in the patients
with frequent VPB's. VF occurred in six of thirty-two patients with
frequent VPB's and in seven of thirty-five without VPB's. In seven
patients R upon Sinus T was seen and four of these had VF. In two
of these VF occurred four and six days after the appearance of the
R upon T phenomenon. Of the seven patients with R upon Sinus T,
therefore, only 25% had VF in the CCU, and of the ten cases of VF
seen, only four fell in the group with R upon T, and two of these
would have been post CCU care by current practice. As a predictor
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of VF on the standard monitoring system, the R upon Sinus T
located, therefore, only two of ten patients having VF in the CCU.
Five patients had R upon ectopic T of V/V form and all five
survived. Ten patients were seen to have runs of between two and
four consecutive VPB's and 20% of these had VF. Cases are
reported by Julian et al where VF occurred despite the abolition of
R upon T ectopics and VT. It was observed, however, that VT of
200/min. lasting seconds or minutes was the usual pattern of
initiation of VF, and was the immediate cause of cardiac arrest.
More recently, significant suppression of R upon T and VT has
been achieved with more modern drugs (Campbell et al, 1973;
Talbot et al, 1973). These studies included too few patients to
demonstrate whether VF was abolished, although VF only occurred
on two occasions, and in the placebo group, of Campbell's study.
A similar pattern of findings to that in the earlier studies
(Lawrie et al, 1968) leads to the statement that VF occurring early
in the course of AMI is rarely preceded by warning arrhythmias,
whereas these are commonly present in the majority of patients
developing late VF. Of their cases of primary VF, 80% were in the
first four hours after AMI and arrhythmic warnings rare. Of twelve
cases of primary VF, only two had warning arrhythmias noted early
enough to allow the institution of therapy, and in two patients on
continuous taped monitoring VF developed thirty seconds after the
appearance of VPB's.
A recent prospective study in 206 patients (Mogensen, 1970)
using continuous slow speed paper print out of the ECG, demon¬
strated the R upon T phenomenon (Definition of Lown, 1969) in only
ten patients, (i.e. 2% of all patients). There was only one CCU
death among the patients with R upon T and five late deaths. VT
occurred in 40% of all patients and 16% of patients with VT died.
VT occurred most commonly in the first twelve hours and was
mostly in those admitted before three hours had elapsed from the
onset of symptoms. VF occurred in 6% of all patients and in 26%
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of the patients with VT. Primary VF occurred in 2% of all patients
but was not restricted to those with the R upon T phenomenon. A
moderate association only was found between VT and R upon T,
whereas a strongly significant association was present between VT
and frequent and multifocal VPB's.
Retrospective analysis of the fourteen patients with VF showed
that six were seen to have R upon T, and in eight the phenomenon
was not observed. Of the six with R upon T two had primary VF
and four had complicating VF. Of the eight without R upon T, three
had primary VF and five had complicating VF. This important data,
therefore, fails to demonstrate a specific relationship between R
upon T and primary VF in the clinical situation of AMI in man.
Mogensen concludes that the earlier clinical and experimental
evidence of R upon T initiating VF remains a strong case for
treatment, but qualifies the statement by saying that the mode of
onset of VF is rapid VT in most patients not on Lignocaine, often
with preceding R upon T or multifocal VPB. In his later
Lignocaine studies, Lignocaine was less effective against R upon
T than other forms of VPB.
Similar proportions of patients having VF have been reported
(Day and Averil, 1966; Adgey et al, 1971) with the higher incidences
being in those groups seen earliest. A pattern of 10% of patients
having VF in the first hour, 12% in the second and 2% in the third
hour is the most commonly reported.
VT is detected more commonly with continuous ECG monitoring
(Mogensen) and is common during periods of Sinus bradycardia.
The episodes are not normally associated with a worse prognosis
during AMI (Rothfeld et al, 1968; Norris and Yates, 1970).
The most recent complete analysis of a series of continuously
tape-monitored patients with AMI is that of Vellani who showed that
in a series of 100 patients, twenty-six had R upon T VPB's which
were commonly isolated, but sometimes repetitive. S/V forms
were seen in nine patients and V /V forms in twenty patients. Of the
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twenty-six patients with R upon T only seven had VF. There was no
obvious time relationship between VF and the R upon T events. This
may be a function of the variable period of recording before VF
occurred. VT tended to occur late and was seen in 70% of patients.
This confirms the impression that short runs of VPB are a poor
predictor of VF.
VF occurred in a total of thirteen patients, six of whom had VF
without R upon T phenomenon, and only three of the thirteen had
primary VF. The inter-ectopic R-R intervals preceding the VF
showed a steady decrease in most cases, commonly falling by
40-60% from the first to the last interval before VF ensued. This
pattern is comparable with Mogensen's finding of VT initiating VF
and to Lown's VT of the vulnerable period.
The association between these arrhythmias and VF has been
further questioned in two studies of 400 and 262 patients
respectively where no firm relationship was found between
premonitory arrhythmias and VF (Lie et al, 1974 and 1975).
Unfortunately the arrhythmias were mot classified in comprehensive
detail and the monitoring systems have been criticized
Computor monitoring of patients with AMI (Romhilt et al, 1973;
Vetter and Julian, 1975) has revealed large deficits in the detection
of arrhythmias by conventional monitoring procedures. These
findings must question the credibility of all previous reports, but
neither of the computor studies observed sufficient patients to
provide the definitive statement on the relationship between VF and
the other ventricular arrhythmias.
SUMMARY
Both visual and electromagnetic taping methods of continuous
ECG recording have shown that VF occurs in approximately 10%
of patients reaching the CCU, and that VF is commonest in the
earliest hours after AMI. Mobile CCU's confirm the distribution of
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this arrhythmia and make contact with a higher number of cases.
VPB and VT have been demonstrated in 70-90% of patients by
continuous ECG taping and computor monitoring. This is a much
higher incidence of these arrhythmias than reported from visual
monitoring and they must, therefore, be relatively poor predictors
of the individual who will develop VF„ The R upon T phenomenon
appears to be comparatively rare, occurring in approximately 2%
of patients on continuous taping. Its relationship to VF is less
definite on clinical grounds than previously predicted from the
results of animal experiments. Nevertheless, in practice the R
upon T phenomenon is still widely used as a principal indication for
prophylactic antiarrhythmic therapy.
CHAPTER 4
The Prognostic Significance of Ventricular Arrhythmias in the
Period After Acute Myocardial Infarction
Pel and Dolonso (1964) studied the death rate in 1,180 men with
AMI who had had a routine ECG at any time before the attack. They
showed that during the attack and in the subsequent thirty days
there was a higher death rate in those with any ventricular
arrhythmia before the attack. Tabatznik et al (1972) reporting the
continuous ECG tapes of 160 men who had survived one or more
AMI over three years, showed higher death rates in men with
greater than 10 VPB's per hour, multiform VPB's and VT. These
findings were independent of the other standard risk factors for
CHD.
The Coronary Drug Project (1973) showed that 11. 5% of 2,035
men surviving AMI had one or more VPB's in a single ECG. In a
three year follow up 21.7% of patients with VPB died and 11.4% of
those without VPB died. Excess long term risk was associated with
multiple VPB's and VT, but R upon T VPB although showing the
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same trend did not demonstrate a prognostic significance for
death. Kotler (1971) confirmed these findings in a further 160
men. Lown states that the mere presence of VPB's has little
prognostic implication as 62% of patients with known CHD
monitored for twelve hours have VPB's and, therefore, it is un¬
likely that they can be a powerful discriminant for death of
the individual. Contrary to this view is the report that it is
possible to demonstrate on an ECG of one hour's duration, a
three-fold risk of sudden death in men with complex VPB's
(Ruberman et al, 1977). This recent study attempts some
subdivision of VPB's and although not using the classification
of Smirk, unlike Lown's study it does separate R upon T events
from other complex arrhythmias. At sequential points in time
in the follow up period, men with R upon T or runs of VPB were
at higher risk of sudden death than those with bigeminy or simpler
forms of VPB.
SUMMARY
Ventricular arrhythmias after AMI identify a group with an
independent risk of sudden death greater than that attributable
to the standard risk factors. With continuous records these
arrhythmias are detected more frequently but whilst identifying
an at risk group it remains uncertain if they can identify the
individual who will die suddenly of VF at any time after initial
recovery from acute myocardial infarction. The importance of
specific complex arrhythmias such as R upon T VPB is uncertain,
probably as a consequence of their comparative rarity and poor
detection by conventional survey methods. Nevertheless,
continuous recordings do confirm that the detection of any complex
arrhythmia may be helpful in locating at risk patients.
CONCLUSION TO PART 1
The evidence that any one ventricular arrhythmia, and in
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particular the R upon T phenomenon, is causally related to
ventricular fibrillation in man has been reviewed and is inconclusive.
Approximately equal numbers of people with the R upon T
phenomenon have VF or escape without VF, and as many people as
have VF and R upon T, have VF without preceding R upon T. A
considerable number have VF without any of the forms of so called
premonitory arrhythmia, particularly in the earliest phases of
AMI. the abolition of VPB's, R upon T forms of VPB, and VT, does
not remove the risk of developing VF although of course the quality
of the therapy given may have influenced the results reported.
It might be postulated that VPB's singly or consecutively may be
the harbingers of sudden death in the presence of myocardial
ischaemia, if each pattern of ventricular arrhythmia represents a
different stage of progression through a series of metabolic
abnormalities at myocardial cell level; the decisive factor for the
development of VF not being inherent in the VPB's themselves, but
in the extent of metabolic disturbance which has allowed the
appearance of each type of arrhythmia.
The rate at which myocardial metabolic inhomogeneity develops
during ischaemic episodes may vary with the individual, and depend
upon the extent of the disease of the arterial tree and the state of
development of the collateral circulation. For example, a person
with triple vessel disease and a sedentary mode of life might,
during an acute ischaemic attack, develop local areas of metabolic
imbalance, because of the lack of the facility to clear rapidly
abnormal accumulations of metabolites. This would lead to early
inhomogeneity of fibre activity and substantially increase the risk
of VF. In other individuals a slower development of these changes
would occur because of at least temporary local compensation
achieved by opening of collaterals. A stepwise deterioration would
then occur as the thrombotic process spread and ultimately
exceeded the capacity of the compensatory mechanism. VF would
then ensue. Each step in the metabolic deterioration in a given area
20
would allow of a different pattern of disorganised impulse formation
and conduction, and, therefore, each successive arrhythmia would
effectively give warning that the metabolic situation at myocardial
level was deteriorating, and that the conditions allowing VF to occur,
by whatever mechanism, were imminent. This progressive pattern
is seen in occlusion of the coronary arteries in normal dogs and may
represent the situation in some of the patients surviving to reach
the CCU. This would give the impression in the CCU situation that
these "premonitory" arrhythmias were in fact causally related to
VF. The prognostic grading of the arrhythmias (Moss et al, 1975)
could, therefore, be interpreted as an indirect grading of the
degree of metabolic disturbance at myocardial level, in patients
who were to some extent able to compensate at the time of acute
ischaemia and, therefore, did not die suddenly of VF. Each more
severe step in metabolic disorganisation would be less likely to
resolve spontaneously and, therefore, in each successive group of
patients a greater proportion would proceed to VF and death. This
would account for the observed findings that although on experimental
grounds the R upon T phenomenon has been suggested as the cause
of VF, not all patients having R upon T events develop VF. The R
upon T phenomenon could, however, still be the most sensitive
indicator of impending death if, as Vellani suggests, it represents
severe metabolic disorganisation to the extent of potassium
leakage into the channels surrounding the cells. This would not
then attribute the cause of VF to the R upon T phenomenon, but
rather that the phenomenon represents the beginning of the last
stage in deterioration before the conditions occur which favour the
development of VF.
The exploration of the local metabolic changes and the concurrent
systemic manifestations of AMI assume new importance as the mere
removal of the ventricular arrhythmia, by suppression of myocard¬
ial cellular activity, is manifestly inadequate as a therapeutic
measure, and does not necessarily prevent the progression of the
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underlying metabolic changes. Intervention in these cases could,
however, halt their progression and so provide a means of
preventing each successive type of arrhythmia and, therefore,




The vulnerability of the myocardium to the development of
sudden failure of normal rhythm and contraction, must ultimately
depend on the extent of alteration in the normal pattern of cell
metabolism caused by reduced coronary artery blood flow. These
metabolic changes may be precipitated for the first time by acute
massive coronary artery occlusion, or may result from minor
reductions in blood flow in the circumstances of dangerous pre¬
conditioning of the myocardium from repeated earlier minor
episodes of ischaemia. As already indicated in this thesis, the
immediate consequences of any one episode of myocardial ischaemia
do not necessarily progress to irreversible cell destruction even if
they do reach the stage of initiating ventricular fibrillation.
The information about normal myocardial metabolic pathways
has been obtained by study of animal preparations and of isolated
perfused animal hearts. These findings can only be confirmed
indirectly in man by derived measurements of coronary blood flow
and the comparison of arterial and coronary sinus concentrations
of metabolites. The use of exercise, fasting, alteration in diet and
the infusion of safe amounts of test substances, e.g. catecholamines
can give further indirect information about the response of the
myocardial cell to these types of stresses in man. Information
about the effect of acute ischaemia on the myocardium is
restricted to that from experimental coronary artery occlusion in
intact animals and from ischaemic perfused heart preparations. In
man, with acute myocardial ischaemia or infarction the information
about the metabolic changes has been restricted to studies of the
systemic response to myocardial ischaemia, coronary sinus
catheterisation studies, and comparison of the findings with the
changes known to occur at myocardial level in animal experiments.
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The comparability of the response of the human myocardium and
that of animals to reduced coronary blood flow is obviously
questionable, particularly in that clinical myocardial ischaemia in
man is the culmination of a slowly progressive reduction in blood
supply terminated by the acute event, whereas in animal experiments,
relatively sudden reduction of blood flow is achieved in the
previously normal heart.
The elaboration of the thesis, that intervention in the systemic
metabolic abnormality following AMI in man may be reflected in
metabolic changes at myocardial level which will reduce the incidence
of ventricular arrhythmias, requires, therefore, an assessment of
the current knowledge of the normal metabolism of the myocardium
and the effect of ischaemia, as judged from experimental evaluations
in animals. This must be compared with the clinical evidence in man
linking the systemic metabolic response to myocardial ischaemia
with the incidence of ventricular arrhythmias.
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CHAPTER 1
The Metabolism of the Normal Myocardium
The normal myocardium is highly dependent upon oxidative
metabolism of substrates for its supply of energy. During normal
coronary blood flow approximately 75% of coronary artery oxygen
is extracted during the passage of blood through the myocardium
(Scheuer, 1967) and, therefore, only a limited additional amount
can be extracted under abnormal conditions. The most important
substrates normally used by the myocardium for the generation of
energy for contraction and the maintainance of cell membrane
functional integrity, are glucose, FFA, and lactate. To a lesser
extent pyruvate, acetate, ketones and amino acids can be used
(Olson and Piatneck, 1959). A "schematic representation of energy
pathways in the normal myocardium is shown in Figure 3.
Plasma FFA are generally believed to be the major source of
FFA for myocardial metabolism (Bing, 1965) and their relative
contribution probably accounts overall for 30-40% of total substrate
utilisation. They may account for a much greater proportion in
severe fasting states, and the fractional contribution of FFA thus
varies with the state of fasting and exercise. The concept of
substrate competition for oxidation and its effect on the contribution
of FFA is reviewed by Opie (1969). He concludes that carbohydrate
may become the major fuel during significant parts of the 24 hour
cycle, especially during periods of prolonged exercise.
Under physiological conditions FFA are extracted by the
myocardium in preference to carbohydrates (Ship et al, 1961) and
a positive correlation has been demonstrated between the arterial
concentration of FFA and myocardial extraction or uptake of FFA
(Scott et al, 1962). It is suggested that FFA are not subject to active
transmembrane transport and that their uptake is a non-energy
requiring process. It may, however, be influenced, at least in
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Figure 3. Energy Pathways in The Normal Myocardium.
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experimental conditions, by the albumin:FFA ratio and by the
degree of unsaturation of the FFA (Evans, 1964). When FFA in
excess of requirements is taken up, it is stored as triglyceride and
phospholipid, and during extremes of exercise and fasting,
oxidisable FFA may be released from triglyceride by the action of
myocardial lipase.
Glucose uptake is an active, energy requiring process and
therefore is limited by the availability of its carrier (Morgan et al,
1961). Insulin accelerates membrane transport of glucose, and thus
in the presence of adequate insulin the rate limiting step for the
uptake of glucose becomes the rate of intracellular phosphorylation.
In addition there is a threshold level below which glucose cannot be
taken up, although its mechanism is uncertain. When excess glucose
is taken up it is stored as glycogen which can be utilised as a
source of energy in extreme circumstances. The operation of an
FFA/glucose cycle has been proposed as an explanation of the
control of glucose uptake and it has recently been shown that
decreased plasma FFA after nicotinic acid administration is
associated with increased glucose uptake (Balasse and Neef, 1973)
and that increased FFA after high fat feeding is associated with a
decreased glucose uptake.
Intracellular transport of substrates is necessary for their
entry into the energy trapping cycle located in the mitochondria,
and thereafter the main substrate catabolic pathways of glycolysis,
beta-oxidation and 2 carbon degradation with the generation of high
energy phosphate compounds do not differ materially from those of
other tissues. The major dependence in normal circumstances on an
aerobic pattern is borne out by the low content of anaerobic
enzymes and high concentrations of cytochromes, with the
oxidation of ADP-ATP as the final step in the energy formation in
the myocardium.
The maintainance of the transmembrane electrical potentials,
ultimately responsible for the electrical activity of the heart,
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depends in part upon the maintainance of transcellular ionic
"I" "f"
gradients (Hodgkin and Horowicz, 1959). The Na and K pumping
mechanisms are linked to specific ATPase systems which depend
in turn on ATP for energy. This system in the heart appears to be
located in the sarcotubular system (Krespi et al, 1964). If ATP
supplies are jeopardised then both the electrical and contractile
activities are compromised.
SUMMARY
In the normal heart the metabolic pathways form a well
integrated system which is controlled by the relative quantities of
high energy compounds and by their breakdown products. It is also
influenced by the provision of oxygen and a balanced supply of
essential substrates for aerobic breakdown. The most important
substrates are FFA and glucose which are taken up by differing
mechanisms. Each may assume relative importance under differing
normal conditions although overall, FFA seems to be the major fuel.
A complex cyclical mechanism may exist between FFA and glucose
which determines the relative contribution of each at any given time
of day taking into account conditions of fasting and exercise.
CHAPTER 2
The Metabolism of the Ischaemic Myocardium
In the minutes immediately following experimental coronary
artery occlusion in dogs, a wide area of cyanosis appears on the
epicardium and there is early loss of contractility of myocardial
cells. This initial area of involvement may be much larger than
the final infarcted area. These changes can occur before ECG
changes and arrhythmias appear. The reduction in coronary artery
blood flow results in the maximal extraction of available oxygen
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but the increase obtained is limited, and is inadequate to support
the normal electron transport chain and there is a consequent fall
in the production of ATP. The myocardium must, therefore,
resort in part to anaerobic energy production with the utilisation of
differing proportions of both the usual and alternative substrates
(Opie, 1971).
Glucose consumption increases at the expense of glycogen
storage and the phosphofructokinase reaction is accelerated by
oxygen deprivation (Scheuer, 1967; Owen et al, 1969). This speeds
glycolysis which is also stimulated by ATP breakdown products
and catecholamines. There is a consequent increase in pyruvate
production and in the face of decreased pyruvate utilisation,
pyruvate accumulates and pushes the Lactate-Pyruvate reaction
towards Lactate, an increase in which is probably the one easily
measured myocardial metabolic response to hypoxia (Scheuer, 1967;
Gorlin, 1969). Even this does not, however, directly reflect a
uniform intracellular change throughout the cyanotic area as
inhomogeneity of myocardial blood flow will affect overall
measurements of lactate output.
Anaerobic glycogenolysis is an apparently transient source of
energy in intensely anoxic areas only in the earliest phases of
ischaemia, but it ceases before the complete exhaustion of glycogen
stores (Opie, 1968).
The accumulation of lipid droplets in the animal myocardium
occurs within 2-6 hours of breathing an hypoxic atmosphere
(Wartman et al, 1956). This occurs only in living cells and not in
rapidly dying cells. The findings are confirmed in man (Scott, 1961)
by study of the myocardium of children dying hypoxic deaths.
Uptake and storage of FFA take place under hypoxic conditions as
long as there is sufficient glucose present to support an actively
glycolysing system, and as FFA uptake is non-energy requiring it
continues despite a diminishing supply of ATP. An adequate supply
of glucose has been shown to enhance FFA incorporation into
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myocardial neutral lipid and suppress oxidation of FFA. Alpha-
glycerophosphate is an important precursor of triglyceride and its
availability affects the extent of FFA esterification. It is an
intermediary product of glycolysis and when present in increasing
concentrations stimulates FFA esterification as in conditions of
partial anaerobic metabolism. During all but severely ischaemic
conditions, i.e. in hypoxic but living cells, anaerobic glycolysis
may produce enough ATP for intracellular transport of FFA and
enough glycerophosphate for its esterification.
In the presence of high plasma FFA concentrations, therefore,
uptake and storage of FFA will result in the appearance of neutral
lipid droplets in the perimitochondrial zones of the cells (Brachfeld,
1969). Complete anoxia with mitochondrial death is the only
situation to completely arrest FFA uptake. Where in addition FFA
utilisation is restricted by oxygen lack which prevents entry into
the Krebs cycle, the overall outcome might be of patchy FFA
accumulation in the myocardium during episodes of ischaemia. A
schematic representation of the energy pathways in the ischaemic
myocardium is shown in Figure 4.
During periods of diminished ATP production the maintenance
of the cell membrane ionic pumps is threatened. Under conditions
of total anoxia ATP disappears from the cell in 15 minutes. At this
stage the ECG begins to show an injury potential due to membrane
malfunction consequent upon potassium leaking from cells. This
alters the extracellular concentration of the ion and thus modifies
membrane depolarisation. In ischaemic dog papillary muscle 10%
of cellular potassium is lost in the first lj hours of ischaemia and
depletion to about 20% occurs by 24 hours (Jennings et al, 1969).
Efflux of potassium from dog heart in vivo after coronary artery
occlusion has also been demonstrated. This potassium loss from
the ischaemic cell has been linked to the occurrence of arrhythmias
although the maximal efflux of potassium into the coronary venous
effluent was not related temporally to the onset of arrhythmias
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Figure 4. Energy Pathways in the Ischaemic Myocardium.
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(Cherry and Myers, 1971). Injection of potassium into patent
coronary arteries, with consequent high extracellular levels, has
been shown to induce ventricular arrhythmias (Harris et al, 1958).
The leakage of potassium from the cells and its accumulation in the
continuous sheath around the conducting system would expose the
cells to very high extracellular concentrations which could affect
the conduction velocity and so allow the propagation of ventricular
arrhythmias.
Extracellular concentrations of other electrolytes such as
calcium and magnesium may also be abnormal. Surowicz discusses
the relationship between relative concentrations of potassium and
calcium and shows that in experimental conditions an imbalance
between potassium and calcium concentrations is more closely
related to severe electrical disturbance than simple potassium loss
from the cell (Surowicz, 1971). The calcium ion is a major factor
along with ATP in the interaction of actin and myosin on which
normal contraction is bas-ed. The loss of ATP and calcium under
ischaemic conditions may thus contribute to sudden failure of normal
myocardial function. Low concentrations of the magnesium ion have
been associated with sudden death and arrhythmias (Chipperfield
and Chipperfield, 1973), and either acute depletion or a critical
alteration in extracellular concentrations during acute ischaemia
following upon chronic depletion, may contribute to the ionic
imbalance which interrupts normal membrane function.
SUMMARY
Under ischaemic conditions the myocardium is obliged to resort
to an increasing extent to anaerobic metabolism. Glucose
consumption is increased at the expense of storage, and lipid
accumulation occurs. This latter effect is accentuated by the
reduction in FFA utilisation as FFA cannot be metabolised
anaerobically and it requires slightly more oxygen for aerobic
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metabolism. Furthermore, FFA inhibits glucose uptake.
Consequent ATP lack threatens membrane ionic pumps and K+
leakage occurs along with changes in relative concentrations of
calcium and magnesium. The combined effects are a deterioration
in membrane electrical stability and hence of conducting and
contractile functions.
CHAPTER 3
The Systemic Response to Acute Myocardial Infarction in Man
The clinical syndrome associated with acute myocardial infarction
in man is accompanied by the early onset of systemic metabolic
changes which result from the acute physical stress situation that
has been induced. Their importance lies in their effects on the
balance of the essential substrates available for support of the
remaining partly ischaemic myocardium. This may be of critical
importance to those areas of myocardium which are not uniformly
ischaemic and contain potentially viable cells. In these regions,
metabolic inhomogeneity and failing energy supply may lead to
membrane instability or ultimate necrosis of the whole area.
The changes in plasma metabolites and hormones are shown in
Figure 5.
Plasma total catecholamines rise sharply within 30 minutes and
remain consistently elevated at almost three times the normal level
for at least 48 hours from the onset of symptoms (Vetter et al, 1974;
Videbaek et al, 1972). Initially the major component is probably
noradrenaline (Jewitt,et al, 1969; McDonald et al, 1969) followed
by an adrenaline response (Gazes et al, 1959) reflected in high
urinary adrenaline during the 24 hours after the onset (Valori et al,
1967). The consequent marked catecholamine mediated /3-receptor
stimulation accounts for the sudden elevation in circulating FFA
(Pinter et al, 1967; Carlson, 1968) which are released by adipose
tissue lipolysis. Plasma FFA concentrations are in excess of
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1000 /iEq/L at half an hour after the onset of symptoms and
reach a peak in the region of 1200 juEq/L two hours later. A
fall towards normal levels commences within the first twelve
hours and the normal range is regained by 24 hours in most
instances. The rise is attributed to increased output from
adipose tissue rather than reduction in tissue uptake (Carlson,
1968; Gupta et al, 1969), although this may be altered in
patients with shock and poor tissue perfusion. Increased
adipose tissue lipolysis also results in increased circulating
glycerol concentrations (Carlstrom and Christensen, 1971).
Another possible stimulus to lipolysis is the increased Cortisol
secretion in response to increased ACTH output (Nitter-Hague
et al, 1972; Vetter et al, 1974). Glucose utilisation is impaired
and poor insulin secretion has been reported in severely ill
patients (Taylor et al, 1969). In the earliest phase plasma
immunoreactive insulin is in the low normal range and in some
cases may be subnormal.
Hypoxia alone may initiate these processes but does not peruse
inevitably cause arrhythmias (Harris, 1966) and thus additional
adverse conditions must exist before ectopic excitation can
occur. Preconditioning of the myocardium may exist with lipid
accumulation, but increased local and systemic catecholamine
activity (Maling and Moran, 1957; Ceremuzynski et al, 1969),
and K+ leakage from the cells (Cherbakoff et al, 1957; Regan
et al, 1967) are some of the acute factors. Increased concentrations
of circulating unbound FFA may also have an effect by producing
an increased local concentration which may then have a detergent
activity on the cell membranes (Kurien and Oliver, 1970) or inhibit
ATP transport across the mitochondrial membrane (Shug and
Shrago, 1973).
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Figure 5. Changes in mean concentration (- S.E.M.) of plasma
metabolites and hormones in sixteen patients with AMI
(Adapted from Vetter, et al 1974).
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SUMMARY
Of these systemic metabolic abnormalities occurring as a result of
coronary artery occlusion, no single change so far observed can account
for the development of ventricular arrhythmias or has been solely
related to death in the acute episode. It seems probable, however,
that very early therapeutic intervention would be required to reverse
any of these changes in order to support endangered areas of myocardium
sufficient to influence the clinical outcome of the event.
CHAPTER 4
The Experimental Evidence that Raised Plasma FFA Concentrations
Can Have Deleterious Effects on the Ischaemic Myocardium
In experimental circumstances FFA have been shown to increase
myocardial oxygen consumption (Mj</s, 1971), decrease contractility
(Henderson et al, 1970), alter electrical conduction (Connor et al, 1963),
increase infarct size (Kjekshus and MjjzSs, 1973; Sobel et al, 1973) and
possibly cause overt ventricular arrhythmias (Kurien et al, 1971;
Oliver et al, 1972). In aerobically perfused, contracting, isolated rat
hearts, myocardial oxygen consumption (MVC^) can be altered by varying
the supply of substrates to the myocardium (Challoner and Steinberg,
1966). Specific free fatty acids increase the MVC^ of the potassium
arrested heart and the effects of adrenaline on this preparation include
an increase in the intracellular FFA concentration. This evidence has
been confirmed in the normal contracting dog heart under controlled
haemodynamic conditions (Mj0s, 1971). Infusion of intralipid and heparin
produced plasma FFA levels up to 3000 jtiEq/L which in the presence of
unchanged mechanical performance increased MVOg by about 20%. This
was largely attributed to an increase in metabolic rate stimulated by high
FFA concentrations.
The infusion of high concentrations of FFA into dogs produces
massive platelet thrombosis and death (Connor et al, 1963) but where
the thrombosis is prevented by the administration of heparin,
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FFA still depresses myocardial contractility to the point of death.
FFA administered to rabbits (Severeid et al, 1969) decreased
coronary blood flow and the amplitude of contraction but the effect
was modified by incubation of the FFA with albumin. This suggests
that unbound FFA are particularly toxic to the myocardium. In
experiments in the isovolumically contracting heart (Henderson et al,
1970), high FFA decreased contractility, increased the end-diastolic
pressure and increased oxygen utilisation for a given tension
development. This was accompanied by a decrease in MVC^ which
is contrary to previous findings and is explained on the grounds
that the hearts may have been oxygen limited. The depressant effect
of FFA in these experiments was increased by increasing the
FFA/albumin ratio and a maximum effect was obtained at a ratio of
6:1. It has been further demonstrated in rat papillary muscle that
increasing hypoxia reduces the need for increasing FFA/albumin
ratio to produce myocardial depression, but that increased ratios
prolong the period needed for recovery on re-oxygenation of the
preparation (Henderson et al, 1970). There is also a relationship
between epicardial ST elevation and free fatty acid/albumin ratios
during coronary occlusion in dogs (Miller et al, 1976). In intact
dog hearts the mechanical performance can be modified by FFA in
ischaemic states (Kjekshus and Mj/s, 1972). The raising of FFA
can cause ventricular decompensation which is reversed by the
infusion of glucose and insulin with consequent lowering of FFA.
Agents which increase myocardial oxygen demand have been shown
to increase the size of the experimental myocardial infarction
(Maroko et al, 1971). By inference, therefore, it might be expected
that increased FFA concentrations, by increasing Og consumption,
might increase the size of an infarction. This is supported by
evidence that where FFA are lowered by /3-pyridyl-carbinol
(converted to Nicotinic Acid in the liver)(Kjekshus and Mj/s, 1973)
in experimental infarction, the sum of the ST elevations over the
surface of the myocardium is reduced. The increasing sum of ST
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elevation and the rising FFA produced by the infusion of
Isoproterenol, is. also controlled by nicotinic acid. A similar effect
has been observed with noradrenaline and nicotinic acid and further,
that Ronicol used to inhibit an Isoproterenol induced elevation of
FFA, also reduced the ST elevation (Lekven et al, 1973).
In other animal experiments, the reduction of FFA uptake,
favouring, therefore, glucose metabolism, resulted in the reduction
of ischaemic damage (Mj^s, 1976), and the corollary was true when
glucose metabolism was stimulated by dichloracetate and the degree
of ST elevation was seen to be restricted (Mj^s et al, 1976).
The reduction of plasma FFA by pretreatment with p-chloro-
phenoxyisobutyrate is associated with a decrease in the myocardial
extraction of FFA and with the reduction of the area of ischaemic
injury (Mjjzfs et al, 1976).
Chest wall ST mapping in man has been used to show a reduction
in ST depression in men exercised to the point of anginal pain,
where the nicotinic acid analogue described later in this thesis was
used to inhibit adipose tissue lipolysis and hence lower plasma FFA
(Luxton et al, 1976).
Attempts to produce ventricular arrhythmias by elevating plasma
FFA in experimental animals have produced conflicting information.
Initial studies using the intravascular hydrolysis of triglycerides by
heparin, with consequent release of FFA, were carried out in
mongrel dogs. Elevation of FFA in the presence of AMI was
frequently associated with an increased frequency of VPB and
occasional ventricular tachycardia. This effect was reversible by
Protamine Sulphate which prevented further lipolysis and lowered
the plasma FFA. Arrhythmias occurred 20-30 minutes after peak
FFA concentrations were reached, and further, it was shown that
catecholamine infusion elevated FFA and produced arrhythmias
which could again be modified by lowering the FFA with an analogue
of nicotinic acid (Kurien and Oliver, 1971).
A second series of experiments in mongrel dogs (Kurien et al,
1971) confirmed these findings, but emphasised that the levels of
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plasma FFA required to produce arrhythmias were in excess of
those seen in man and that heparin itself may alter the composition
of myocardial FFA. Albumin bound FFA was then produced with a
similar FFA composition to that of dog plasma and it was infused
to elevate the plasma FFA to levels seen in man with AMI. The
initial experiments of this type confirmed the appearance of more
arrhythmias in the treated than in the control group. A more
extensive series, however, failed to support these findings and
profound hypotension during the infusions, with its haemodynamic
consequences, rendered the results inconclusive (Riemersma et al,
1974). Parallel experiments in 36 greyhound dogs and in a further
5 mongrel dogs did not support the earlier findings (Opie et al,
1971), although the same method of elevating FFA was used.
Elevation of FFA to 6000 /xEq/L and priming of the myocardium
with lipid failed to produce any excess of arrhythmias. The
complete absence of arrhythmias in these experiments has never
been explained despite differences in experimental material. It is
possible, however, that other factors which predispose to the
development of arrhythmias were altered, such as higher heart
rate, pericardectomy and coronary artery ligation with
interruption of the sympathetic nerve supply, and modification of
local catecholamine concentrations. The same workers have,
however, produced ventricular arrhythmias in isolated rat hearts
using unbound FFA (Opie, 1970).
An alternative approach to the problem in a small series of
experiments was that in which adipose tissue lipolysis was
inhibited and the effect on the naturally occurring incidence of
arrhythmias considered. A significant reduction in incidence of all
VPB was recorded with antilipolytic treatment but a direct anti¬




The accumulated experimental evidence from in vitro and in
vivo work in animals indicates that FFA have a metabolic
stimulant effect on the myocardium, and if present in excess in
hypoxic conditions, can produce an increase in oxygen demand which
cannot be met. FFA have been shown to increase MVOg in normal
dog hearts and to decrease contractility in hypoxic conditions. This
is accentuated when the FFA/albumin ratio exceeds 2:1 with a
consequent rise in the amount of unbound FFA being presented to the
myocardium. FFA also have been shown to increase the output of
creatine kinase from the damaged myocardium, and the area of ST
elevation produced by hypoxia alone. These effects can be
partially ameliorated by inhibition of lipolysis by various agents
and alteration in the relative amounts of FFA and glucose made
available to the myocardium. This implies that FFA can play some
part in determining the area of disturbance of membrane function,
and, therefore, may influence the extent of the ischaemic damage.
Whilst this evidence mitigates firmly in favour of high
concentrations of plasma FFA having adverse effects on infarct
size and mechanical performance, the experimental evidence that
FFA can cause ventricular arrhythmias is less decisive. The
attempts to precipitate arrhythmias in dogs have been successful,
but the FFA composition of the infusates and the very high plasma
FFA levels achieved influences the interpretation of the results.
Attempts to meet these criticisms were successful in that arrhythmias
were apparently produced in a further series of animals, and whilst
the arrhythmias were of the types seen in man, and were frequent,
formal comparison with a control group failed to show a
statistically significant higher incidence.
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CHAPTER 5
The Clinical Relationship Between Elevated Plasma FFA
and Arrhythmias in Man with Acute Myocardial Infarction
There is a marked rise in plasma FFA in patients with AMI.
This was first described in 1966 (Kurien and Oliver, 1966) and has
been confirmed by further studies (Gupta et al, 1969;Gupta et al,
1972;Hagenfeldt and Wester, 1973; Jadraque, 1972; Nelson, 1970;
Oliver et al, 1968; Prakash et al, 1971; Ravens and Jipp, 1972;
Reimann and Schwandt, 1971; Rutenberg et al, 1969; Sznajderman
et al, 1973). Plasma FFA begin to rise within the first 30 minutes
after the onset of symptoms and reach a peak in the region of
1200 pEq/L 1-2 hours later (Vetter et al, 1974). Levels then
decrease towards normal by 24 hours after AMI, as shown in
Figure 6. The clinical relationship between this rise in FFA and
the complications of AMI was first suggested by Kurien and
Oliver when death occurred in 3 patients in their study and all
were observed to have FFA in excess of 1000 pEq/L. This
included the patient with the highest FFA of all in the study (Kurien
and Oliver, 1966). A subsequent study of 200 patients (Oliver et al,
1968) related each of the clinical complications of AMI to FFA
concentrations. "When plasma FFA > 1200 pEq/L were recorded,
a significantly higher number died early in the illness, and during
the follow up period. A significantly greater number had serious
ventricular arrhythmias or conduction defects in the presence of
these levels of FFA. The finding of a relationship between
elevated plasma FFA and ventricular arrhythmias was confirmed
by Gupta (Gupta et al, 1969) in 35 patients but refuted by Rutenberg
(Rutenberg et al, 1969) in 78 patients on the grounds that the
admission FFA was not related to complications later in the illness.
There was, however, "a decisive trend for FFA to be elevated at
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Figure 6. Plasma Free Fatty Acid Concentrations Following Acute
Myocardial Infarction in Man.
(From Oliver, Rove and Vetter in 'Effect of Acute Ischaemia
on Myocardial Function').
L2
atrial contractions, ventricular arrhythmias and heart block...."
Subsequent analysis of this study using a dividing line of plasma FFA
concentrations of 1200 /xEq/L failed to confirm the earlier findings
of Kurien et al (Rutenberg and Soloff, 1970).
The failure of admission FFA to predict complications was
supported by Nelson, but no relationship with peak plasma FFA was
attempted in the study and artificial elevation of FFA with heparin
was not associated with the immediate onset of complications
(Nelson, 1970).
Positive correlations between elevated FFA and complications
of AMI were demonstrated by Prakash (Prakash et al, 1971) in 21
patients of whom 4 died, where FFA > 1100 juEq/L were related to
complications, and by Gupta (Gupta et al, 1972) where 8 of 60
patients died and all had marked elevation of plasma FFA. The mean
plasma FFA concentrations in this group at the time of onset of
complications was higher than that in the non-complicated group.
Jadraque confirmed these findings (Jadraque, 1972) with the
exception of a negative relationship between FFA concentrations and
both heart block and supraventricular arrhythmias. As in later
studies by Hagenfeldt (Hagenfeldt and Wester, 1973) the mean plasma
FFA for the group was lower than usually observed. The study of
Hagenfeldt is interpreted as contradictory to a relationship between
FFA and serious arrhythmias. These results are, however,
difficult to compare with previous studies as the FFA methodology
differed, producing overall lower estimates of plasma FFA, and all
arrhythmias were considered together without distinction into
sub-groups. Only 3 patients had serious ventricular arrhythmias
and there were no deaths. This suggests a selected group of
relatively uncomplicated patients with lower plasma FFA. Even so,
there was a positive correlation within this group between FFA and
clinical severity including non-specific symptoms such as vomiting.
Ravens and Jipp, in 1972, showed in 25 patients a trend towards
high FFA with arrhythmic complications, and Sznajderman, in 1973,
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in 70 patients showed higher FFA in complicated infarctions, and a
longer duration of elevation of plasma FFA in the 14 patients who
died. These studies are summarised in Table I.
SUMMARY
Numerous studies have shown a marked increase in plasma FFA
concentrations in patients with acute myocardial infarction. The peak
elevation occurs 1-2 hours after infarction and in those studies in
which serial sampling was undertaken the peak appears to be in the
region of 1200 pEq/L. Peak levels are maintained for a few hours
only, and normal levels are achieved within 24 hours. The weight
of clinical evidence is in favour of a positive relationship between
the extent of the elevation of FFA and the occurrence of serious
complications and death in the acute phase, and in the Oliver
experience, with death in the later phase of the illness.
A complicated course- and the appearance of ventricular
arrhythmias is associated in most studies with plasma FFA
concentrations on at least one occasion during the first 24 hours of
greater than 1000 /iEq/L, and in the case of subsequent death,
levels in excess of 1100 p.Eq/L are commonly recorded. There is
no evidence that a single measurement of FFA on admission to
hospital can predict the clinical course of the illness in the
individual. The type of complication related to high FFA is also
variable, as Oliver found high levels in patients with cardiogenic
shock, a finding so far unconfirmed, and directly contradicted by
Rutenberg who found low FFA in the "Shock Syndrome" with poor
peripheral perfusion. Oliver's finding of a relationship with A-V
block is not confirmed by Jadraque. In most instances serious
ventricular arrhythmias have been positively correlated with high
FFA although it is necessary to be cautious in this interpretation
because of the variable time periods over which the ECG was
recorded, and the inconsistency of recording methods.
u
Table 1.
Clinical Studies of Relationship between Raised Plasma FFA Concentrations and
Complications of Acute Myocardial Infarction in Man
Author Number of Phs. Number of Deaths Support for Hypothesis
That ^Plasma FFA =




1966 20 3 + ve
Oliver, Ku.irien
and Greenwood
1968 200 32 + ve
Gupta
1969 35 0 + ve
Prakash
1971 21 4 + ve
Gupta
1972 60 8 + ve
Jadraque
1972 50 8 + ve
Sznajderman
1973 70 14 + ve
Nelson
1970 24 0 - ve
Von Ravens and
Jipp
1972 25 0 - ve
Hagenfeldt
1973 24 0 - ve
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CONCLUSION TO PART II
There are two possible interpretations of this relationship
between elevated plasma FFA and the complications of AMI.
The first is that the FFA elevation is merely a reflection of
enhanced catecholamine activity, and that it is a result of various
degrees of systemic metabolic disturbance due to the development
of complications of differing severities.
The second interpretation is that the higher FFA elevations
precipitate further local metabolic disturbance in the myocardium
with consequent development of arrhythmic and other complications.
None of the clinical or experimental observations so far described




The suppression of adipose tissue lipolysis in man with
consequent lowering of the plasma FFA would provide a mechanism
for the exploration of the hypothesis that elevated plasma FFA in
acute myocardial infarction may cause ventricular arrhythmias,
Nicotinic acid is a known inhibitor of adipose tissue lipolysis and
lowers the FFA in normal man for a period of two hours following a
single oral dose of 500 mg. This lowering is followed by an acute
rebound in FFA to levels often in excess of the initial concentration
(Pereira and Mears, 1971). Nicotinic acid is not suitable for
experimental use in patients with acute myocardial infarction,
however, since it leads to peripheral vasodilation and hypotension,
and an increase of 20-30% in cardiac output with an associated
tachycardia (Carlson and Orb, 1962; Ekstrom-Jodal et al, 1970).
The development of analogues of nicotinic acid has, however,
dissociated to a considerable extent the antilipolytic effect of the
parent substance from its haemodynamic effects, and the
experimental work described in this thesis is based on the use of
one such analogue of nicotinic acid which lowers raised plasma FFA
in both animals and man, and has no significant haemodynamic
effects.
Material
The analogue used was 5-fluoro-3-hydroxy-methyl-pyridine
hydrochloride which is metabolised a 5-fluoro-nicotinic acid. The
structures of nicotinic acid and some of its derivatives are shown
in Figure 7.
It will be described in this thesis as a nicotinic acid analogue












5-fluoro-nicotinic Acid 5, Fluoro -
3-Hydroxymethyl-pyridine
Hydrochloride
Figure 7. Structures of Nicotinic Acid and some derivatives.
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would lower plasma FFA within 20 minutes of the administration of
200 mg of the base in an oral capsule, and maintain suppression of
FFA for a period varying from 2 to 4 hours depending on the
individual subject. In dogs, skin flushing was rare, and there was no
increase in the hind leg blood flow.
Biochemical Methods
Throughout the work presented in this thesis, serial measure¬
ments were made of plasma FFA estimated by the Dole method
using the Trout modification and two acid washes (Trout et al, 1960).
The total catecholamines were measured by a tri-hydroxy-indole
method (Carruthers et al, 1970) and blood glucose by an automated
glucose oxidase method (Middleton and Griffiths, 1957). Plasma
triglycerides were estimated by an automated method (Kessler et al,
1965) and in experiments with patients with acute myocardial
infarction, the serum creatine kinase levels were measured by the
method of Smith (Smith, 1967).
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RESULTS
Effect of NAA on Healthy Men
The effect of the NAA on plasma FFA in normal men was
assessed in 8 healthy, fasting, non-obese men, aged 24-47 years,
and with a mean height-weight index of 1,85 (range 0.85-2.1). The
subjects were rested for 30 minutes; venous blood was withdrawn
twice during the resting period, and 200 mg of NAA was then given
orally. Blood was then taken every 15 minutes, for 2 hours, and
then at 3 and 4 hours after the administration of the drug.
Plasma FFA levels began to fall within 15 minutes of the
administration of the NAA. See Figure 8.
Lowest levels were reached at 2 hours from the administration
of NAA with a mean maximal fall for the group of 42% from the
starting value (range 23-56%). The plasma FFA returned to pre-
treatment levels by the fourth hour. The pulse rate (mean rate
65 beats per minute), blood pressure (mean systolic pressure
115 mm of mercury, mean diastolic pressure 69 mm of mercury)
and blood glucose (mean 72 mg%) at the start of the study did not
change throughout the experimental period of four hours. Four men
had minor flushing of the skin restricted to the face about 12
minutes after taking the NAA and this faded in all cases within 2
hours.
Effect of NAA After Noradrenaline Infusion in Healthy Men
Sympathomimetic agents increase plasma FFA in normal men
(Pilkington et al, 1966). In pilot studies sublingual isoprenaline
produced unreliable FFA elevation, but i.v. infusion of isoprenaline,
adrenaline and noradrenaline all produced more consistent results.
Noradrenaline infusion produced consistently the highest FFA









Figure 8. Changes in Plasma FFA concentration in 8 Normal
Men after Oral Administration of 200mg. NAA.
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of NAA on raised plasma FFA in normal men.
After an overnight fast, three normal healthy non-obese men,
including the author, were rested for 30 minutes before the experiment.
A 14G needle was used for sampling from the left antecubital vein,
and its patency was maintained by a saline infusion. After 30 minutes
a 14 gauge needle was introduced into the right antecubital vein for
infusion of noradrenaline in saline over a period of 30 minutes, at a
dose rate of 0.1 mg/Kg/minute. Blood samples were obtained every
five minutes during the infusion, and at 10, 20 and 30 minutes after
the end of the infusion. Each man acted as his own control, and was
given, with an interval of a week, and in this order, noradrenaline
in saline infusion alone, noradrenaline in saline infusion plus 200 mg
oral NAA in a single dose, and noradrenaline in saline infusion plus
50 mg intravenous NAA, with the latter given as a single intravenous
injection over 5 minutes.
Figure 9 shows that infusion of noradrenaline was followed within
10 minutes by a rise in plasma FFA, and this lasted until the end of
the infusion when levels fell rapidly towards normal. The mean
maximum level of FFA reached was 1663 juEq/L (range 1530-1800).
Infusion of noradrenaline followed by 200 mg of oral NAA, given
immediately after commencement of the infusion, showed that NAA
curtailed the increase in plasma FFA. This effect was maintained
despite the ongoing infusion and lasted until the end of the infusion
period and for the subsequent 30 minutes. The effect of 50 mg of
intravenous NAA given 15 minutes after the commencement of the
infusion was similar. Blood glucose concentrations and plasma
triglycerides remained within the normal limits and were unaffected
by noradrenaline infusion or by NAA. Slight flushing occurred,
restricted to the face, in one man on both occasions that the NAA
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Figure 9. Effect of a single dose of NAA given orally (200 mg.)
or intravenously (50 mg.) on Noradrenaline - induced
elevation of plasma F.F.A.
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Haemodynamic Effects of NAA in Patients with
Acute Myocardial Infarction
Minor skin flushing has been described during the preceding
studies of NAA in normal men, although this was not associated
with a rise in pulse rate, or a fall in the blood pressure as
measured by the sphygmomanometer cuff. These apparently minor
changes were in keeping with the pharmacological evidence obtained
in animals. Nevertheless, before proceeding to large scale
investigations it was considered important to determine whether
these effects would be magnified in patients who had recently
suffered an acute myocardial infarction.
The haemodynamic effects of NAA on the systemic circulation
were, therefore, investigated in 5 men with acute myocardial
infarction. In all, the course of the infarction had been uncomplicated,
and none of them had any medicaments within the 12 hours prior to
the investigation. The study was performed 24-36 hours after the
onset of symptoms of acute myocardial infarction with the informed
consent of the patient. For continuous measurements of arterial
blood pressure, a nylon cannula was placed percutaneously in the
left brachial artery, and a long nylon catheter was introduced
percutaneously through an antecubital vein into the superior vena
cava. The arterial pressure was measured by means of an electro¬
mechanical pressure transducer (Statham P23DG) and the cardiac
output by means of a dye dilution technique using indocyanin green
("cardiogreen").
The arterial pressure, cardiac output, and plasma FFA
concentrations were recorded every 15 minutes for half an hour
before and one hour after the oral administration of a single
capsule containing 200 mg of NAA (see Figure 10).
The cardiac index (CI) fell slightly in 4 patients, and in 1 patient
there was a slight rise. Maximal mean decrease in CI was 16%.












































■Figure 10. Haemodynamic effects (Mean * S.E.M.) of a single oral dose
of 200mg. of N.A.A. in five patients with myocardial infarction.
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NAA and would be expected during serial estimations of the CI in
resting patients becoming accustomed to the technique. The heart
rate remained unchanged, the arterial pressure showed a maximal
rise of 4 mm of mercury, and the stroke index did not change
significantly. The rise in total peripheral resistance was related to
the small change in CI. In all 5 patients left ventricular work
decreased slightly and the mean maximal fall in left ventricular
work was 14% for the whole group.
These five patients also showed a mean fall in plasma FFA
concentration of 50% after they received NAA. Plasma total
catecholamines were measured in 3 patients during these studies
and were within the normal range and showed no change over the
whole period of the experiment.
It was concluded, therefore, that when given to patients with
acute myocardial infarction this NAA had no major haemodynamic
effect which might endanger the patient or influence the outcome
of a study of its effects on FFA in such patients.
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Effects of NAA on Plasma FFA in Patients with
Acute Myocardial Infarction
In this series of experiments and in all subsequent experiments
with patients with acute myocardial infarction, informed consent
was obtained from each patient for the administration of this
substance which had no known serious side effects, and which at a
later date might be shown to advantageously modify the outcome of
acute myocardial infarction.
Pilot Study 1
To investigate the effect of NAA on raised plasma FFA
concentrations in patients with acute myocardial infarction, patients
were selected with electrocardiographic evidence of acute
myocardial infarction sufficient to warrant allocation to Groups 1.1
or 1.2 of the Minnesota code (Rose and Blackburn, 1968). Clinical
diagnosis was later confirmed by serum creatine kinase and
aspartate amino-transferase levels. Diabetics, patients with cardiac
failure, and those taking drugs which affect plasma FFA were not
considered for entry into the study. Six patients admitted within
12 hours of the onset of symptoms, and with a plasma FFA of more
than 1000 /iEq/L were selected for this pilot study. The mean time
between onset of symptoms and the commencement of treatment
with NAA was later shown to be 9.0 hours, and the mean maximum
FFA concentration before treatment was 1140 juEq/L.
An indwelling catheter with a teflon obturator was inserted into
a forearm vein for intermittent blood sampling. 200 mg of NAA
were given orally in capsule form every 4 hours for 72 hours
(Group 1, Table 2). Plasma FFA and blood glucose levels were
measured three times in the first 2 hours after starting treatment
and on four occasions during the subsequent 4 days.
In all patients given NAA there was a steep fall in plasma FFA
Group
Sex
Mean time between onseta d treatment (hr.)
Mean
max.F.F.A before treatment (pEq/1.)
Fall
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in the first hour, reaching a nadir during the first 2 hours. The
mean maximum fall within the first 2 hours was 54% from the
starting value (range 40-66%). After the initial fall, however, control
of FFA concentration was unreliable, even within the first 24 hours
of starting treatment with NAA. In 3 out of the 6 patients control of
FFA was maintained below 1000 /iEq/L in the first 24 hours. In the
remainder, however, plasma FFA returned to 1000 juEq/L or more,
at least once in the first 24 hours.
For contrast, the plasma FFA changes were studied in 8 other
patients with acute myocardial infarction who were selected in the
same way and given identical placebo capsules on a double blind
basis (Group 3, Table 2). The plasma FFA in this control group
followed a similar pattern to that previously reported. The mean
maximum fall in plasma FFA within the first 2 hours of treatment
with placebo was 2% from the starting level.
The blood glucose levels showed no consistent change during the
treatment period. There was no flushing, or other side effect.
Pilot Study II
Because plasma FFA were not maintained at normal levels in
all patients throughout the first pilot study, and escape from control
appeared to occur for the first time between two and four hours
from the start of treatment, a further six patients with acute
myocardial infarction were given 200 mg NAA 2 hourly for 48 hours.
The selection of patients was the same, and the patients studied
were comparable to those in the previous group (Group 2, Table 2 ).
Figure 11 shows that all patients in this group had a steep fall in
plasma FFA in the first hour, again reaching a nadir within 2 hours.
The mean maximal fall within the first 2 hours was 58% and control
of plasma FFA was maintained in all patients for 24 hours around a
level of 500 juEq/L. This was followed by a rise to approximately
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Figure 11. Effect of 200mg. of oral N.A.A. or placebo given
2-hourly for 48 hrs. in 14 patients with Acute Myocardial
Infarction.
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before treatment was 1400 /xEq/L and the mean time between onset
of symptoms and commencement of treatment with NAA was 7.25
hours (See Table 2 ). Again, there was no consistent change in blood
sugar. There was no relationship in this, nor in the previous group
of patients between the body weight and the success of control of FFA.
The body weights ranged from 45-90 Kg.
During therapy with NAA there was no flushing or adverse side
effect. Within 4 hours of the withdrawal of NAA there was a rapid
increase in the plasma FFA concentrations towards pretreatment
levels. These were exceeded in some cases within 12 hours of
stopping therapy. This rebound phenomenon commonly occurs after
FFA suppression by other means, and in these pilot experiments
was not accompanied by any adverse features.
Conclusions from Pilot Studies
These observations indicate that this NAA which is metabolised
as 5-fluoro-nicotinic acid, has a similar effect on plasma FFA
concentration to that reported elsewhere with nicotinic acid.
Presumably it achieves this effect by a similar suppression of
adipose tissue lipolysis. Unlike nicotinic acid, however, it rarely
produces skin flushing and in those situations in which skin flushing
is seen it is mild, and commonly confined to the face. It has no
significant haemodynamic effects as judged by clinical observation
in normal men, and by formal haemodynamic investigation in patients
with acute myocardial infarction. It is orally active in doses of 200 mg
if given every 2 hours, but control of FFA is unreliable with a less
frequent dosage regime.
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A Double Blind Trial of The Effect of NAA on Plasma FFA
and Ventricular Arrhythmias in Patients with
Acute Myocardial Infarction
A double blind trial of NAA was conducted in patients admitted
to a coronary care unit (CCU) with a clinical diagnosis of myocardial
infarction,, All had severe praecordial pain starting 12 hours or less
before admission to the trial; those in whom the time of onset of
symptoms was doubtful were excluded. All patients with electro¬
cardiographic evidence of infarction leading to classification as
Group 1.1 and 1.2 of the Minnesota code were initially accepted
into the trial. The diagnosis of fresh myocardial infarction was
later confirmed by increased serum creatine kinase (CK)
concentrations. Patients with normal CK were excluded after
completion of treatment but before analysis of the results. The
following groups of patients were excluded from admission to the
trial: those with cardiogenic shock or overt cardiac failure; those
taking drugs known to affect plasma FFA such as antilipolytic
agents, or beta adrenergic blocking drugs; and those with diabetes
mellitus, hypothyroidism treated with thyroxine, and hypertension
treated with methyl dopa. During the trial period, morphine,
diazepam, digoxin, diuretics and other drugs were given to patients
where indicated, but anti-arrhythmic drugs were only given after
serious ventricular arrhythmia had been observed by the routine
monitoring procedure. Thus the initial frequency of a ventricular
arrhythmia could not have been affected by orthodox anti-arrhythmic
treatment or prophylaxis, and the system used for the monitoring
of ventricular arrhythmias during the study was not used as a
basis for routine anti-arrhythmic treatment.
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Informed consent far administration of the NAA and the
withdrawal of blood samples was sought from 82 patients, and 81
agreed to enter the study. They were not consecutive admissions to
the CCU because the number of laboratory analyses made this
impracticable, but no regular omissions took place such as those
admitted during the nights or at week-ends. Consequently the mean
age and sex of the groups studied resembled those of routinely
admitted patients, and the distribution, of admissions by time of day
was also as expected from admissions to the CCU in the previous
year.
Eleven patients were excluded from the overall analysis of the
results: 4 because the ECG tape recorder failed; 3 because of
incomplete therapy; 3 because myocardial infarction was not
confirmed; and one patient died early in the course of the study. A
maximum of 70 patients was, therefore, included in the overall
/
analysis, and the patient who died is described separately. All 81
patients initially admitted to the study were randomly allocated to
treatment with NAA or placebo and of the 70 patients finally
analysed, 34 had been given NAA and 36, placebo capsules.
One capsule of 200 mg of NAA or an identically prepared placebo
was given 2 hourly for 24 hours, starting 15 minutes after the first
blood sample. Blood samples were taken at the start of treatment;




In all patients, serial measurements were made of plasma FFA,
plasma triglycerides, blood glucose, plasma total catecholamines,
and creatine kinase, as previously described.
Assessment procedure for Ventricular Arrhythmias
Continuous magnetic tape recording of the ECG was started on
admission and was continued for 48 hours from the time of
administration of the first trial capsule. Later analysis of the tape
recording was carried out without knowledge of the treatment group
to which the patient had been allocated. The record was replayed
for visual scanning on a 10 line Raster display oscilloscope at 60
times normal speed. The type of display used is illustrated in
Figure 12. The number of isolated ventricular premature beats
(VPB); episodes of 4 or more consecutive VPB; and episodes of
ventricular fibrillation were counted. All episodes of 4 or more
consecutive VPB were printed on to paper and the rate measured
for classification as ventricular tachycardia where the overall rate
was greater than 100 beats per minute. A special hybrid computer
was used for counting when the VPB rate was too high for visual
counting. The computer was also programmed to locate all VPB
with coupling intervals of 400 milliseconds or less, and these were
then printed on to paper for identification of R upon T or R upon apex
T phenomena. While the computer scan was in progress, the ECG
was displayed visually to check that the signals counted by the computer
were individual VPB. R upon T ectopic beats were subdivided into
ectopic R waves interrupting preceding sinus T waves (S /V type of R
upon T) and ectopic R waves interrupting preceding ventricular
ectopic T waves (V/V type of R upon T), as described by Smirk and
Palmer. The R upon apex T was described as an R wave falling within
40 milliseconds of the visually located apex of the preceding T wave.
Examples of these types of T wave interruption as recorded in this
study as shown in Figure 2, Page 12
6&
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Figure 12. 10 Line Raster display unit as used for initial
visual scan of all E.C.G. tape recordings.
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Assessment Procedure for Adequacy of FFA Control
The pilot studies with NAAon man with acute myocardial
infarction suggested that whilst NAA reliably produced a steep
initial fall in FFA the extent of subsequent control during the
remainder of the treatment period might not be so reliable.
Consequently an arbitrary definition was required of the adequacy
of FFA control achieved on this study. "Adequate" control of FFA
by this NAA was arbitrarily defined, therefore, as reduction of FFA
into the normal range (less than 800 /iEq/L) at 12 and 20 hours
after commencing treatment, and failing to reduce FFA into the normal
range at these times was defined as "inadequate" control. More
stringently, "good" control was arbitrarily defined as a 50% fall at
4 hours after the start of treatment plus normal concentrations
maintained at 12 and 20 hours. Failure to achieve a 50% fall at 4
hours or to maintain FFA within the normal range at 12 and 20 hours,
after a 50% fall at 4 hours was classified as "poor" control.
66
Results of Double Blind Trial
Adequacy of Selection and Randomisation Procedure:-
The mean age of the two groups did not differ significantly, being
56.9 years for the NAA group (Range 40-72) and 55.3 years for the
placebo group (Range 35-69). There was a similar distribution of
the sexes between the two groups. The NAA treated group was
admitted significantly later (5.7 hours) than the placebo group (5.3
hours), (p = <0.01> 0.005). This difference results from a skew
distribution of patients admitted in the earliest hours. Of 11 patients
admitted between 4 and 4.75 hours from the onset of symptoms, 9 were
allocated to the NAA treated group compared with only 2 to the
placebo group; and 3 patients admitted between 2.25 and 2.75 hours
from the onset of symptoms in the NAA treated group compares
with 7 admitted in the same period to the placebo group.
Although there were rather more inferior myocardial infarctions in
the placebo group, (NAA group, 17/34, Placebo group 22/36)
the site of the infarction did not differ significantly between the two
2
groups, (x =0.4825 l.d.f. = NS). The mean maximum FFA
concentration before treatment was 1179 /iEq/L in the NAA group
and 1191 /xEq/L in the Placebo group. These concentrations did
not differ significantly ( p = NS ) and were consistent with a group
of patients which did not include any cases with cardiogenic shock or
frank cardiac failure. (Information concerning weight at the time of
admission was not obtained from all patients. The mean body weight
for 17 patients in the N.A.A. treated group was 70Kgm, and
that for 14 patients in the placebo group was 71.35Kgm. p = NS.)
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Plasma F.F.A. Control Achieved.
There was reduction in plasma F.F.A. in all 34 patients
receiving the N.A.A. (Figure 13); 24 were adequately controlled,
and 10 were inadequately controlled. Sixty per cent of patients
had a fall of 50% or more in plasma F.F.A. within 4 hours of
starting N.A.A., although early reduction into the normal range
was not reliably achieved if the initial plasma F.F.A. level was
greater than 1600]U Eq/L. The pattern of maintained reduction
of F.F.A. was, however, variable, and applying the previously
described alternative and more stringent assessment of F.F.A.
control, only 16 of the 34 patients were shown to have good
control. In these there was a steep initial fall of 50% of initial
plasma F.F.A. within 4 hours with reduction into the normal
range for the remainder of the treatment period; in the remaining
18 patients the plasma F.F.A. were poorly controlled.
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TIME IN HOURS
Figure 13. Plasma Free Fatty Acid Concentrations During
Double Blind Trial.
69
The Incidence and Nature of Ventricular Arrhythmias:-
A total of 29,850 ventricular premature beats were recorded of
which 1,871 had coupling intervals <400m. seconds, 489 were R/T
and 131 were R upon Apex T. There were 139 episodes of ventricular
tachycardia and 2 episodes of ventricular fibrillation.
The first recorded episode of each ventricular arrhythmia after
entry into the trial has been used to define the "patient incidence"
of that arrhythmia. The total number of arrhythmic events in each
patient will not be described, because orthodox anti-arrhythmic drugs
were given once an arrhythmic event was noticed by the routine
monitoring procedure and may, therefore, have influenced the
subsequent incidence of any arrhythmia.
1) Ventricular Fibrillation: -
Ventricular fibrillation (V.F.) developed in 2 patients, one from
each treatment group, and plasma F.F.A. exceeded 1000 /iEq/L in
both cases at the time of onset of V.F. The N.A.A. treated patient
developed V.F. 3 hours, and placebo-treated patient 2.25 hours
after the start of treatment. Despite the fact that F.F.A. concentration
was falling rapidly, in neither case had the F.F.A. fallen by 50% of
the starting concentration, nor had the F.F.A. reached the normal
range by the time V.F. occurred.
2) Ventricular Tachycardia:-
Ventricular tachycardia (V.T.) was defined as 4 or more
consecutive V.P.B. with an overall rate greater than 100/minute.
The number of patients in the whole N.A.A. and whole placebo treated
groups having ventricular tachycardia on one or more occasion
did not differ. In the N.A.A. group 19/34 had V.T. and in the
placebo group 22/36 had V.T. (p = N.S.) In patients treated
within 5 hours of the onset of symptoms, there were fewer patients
having V.T. amongst those given the N.A.A., but this trend was
not statistically significant. (See Fig. 14)
When the incidence of V.T. was related to the degree of F.F.A.
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Figure 14. Cumulative Totals of Patients Having Ventricular Tachycardia.
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In patients first treated within 5 hours of the onset of symptoms
there was a significant difference (p = <0.01) in the number with V.T.
when serum F.F.A. levels were reduced to within the normal range
(=800ueq. per litre) at 12 and 20 hours after starting treatment with
N.A.A. (adequate control) when compared with those in whom this
degree of control was not achieved (inadequate control) (Table 3).
There was also a highly significant difference (p = <0.003) in the
number of patients with V.T. in those with good as compared with
those with poor control (Table 3). No patient with good control of
F.F.A. had V.T. The number of patients with V.T. in the placebo
group did not differ significantly from those with poor control of
F.F.A. given N.A.A.
It was clear that the mean times of admission to the trial of these
N.A.A. and placebo sub groups were significantly different. (placebo=
2.7 hours: N.A.A. group = 3.8 hours, P = 0.001, for patients
admitted within 5 hours of onset of symptoms.)
There was no difference between the number of patients with
V.T. in those first treated between 5 and 12 hours from the onset
of symptoms with N.A.A. or placebo. There were more patients
with V.T. in the N.A.A. treated group with adequate control of F.F.A.
(Table 3) when compared with those with inadequate control (p = <0.05)
It was also noted that the mean times of admission to the trial were
different in these sub-groups (adequate control = 6.2 hours: inadequate
control = 8.5 hours, p = 0.05, in patients admitted between 5 & 12 hours
from onset of symptoms). There was no significant difference in the
numbers with V.T. in the good and poor control groups (Table 3).
The 5-12 hour placebo group showed less V.T. (10/21) than the pre-5
hour placebo group (12/15). There was only one patient in the whole
placebo group whose changes in F.F.A. resembled those in the N.A.A.
good-control group, and statistical comparison of these groups was
not therefore possible.
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Time of Onset of V.T. from Start of Treatment:-
The mean time of onset of V.T. in the Pre-5 hour placebo group
was 7.9 hours, and in the N.A.A. treated group was significantly
earlier at 3. 5 hours. ( p = < 0.05). (See Table 4).
When related to the degree of F.F.A. control in patients treated
within 5 hours of the onset of symptoms the mean time of onset of
V.T. in the N.A.A. "poor control" group was 3.5 hours compared
with 7.6 hours in the equivalent placebo group. (There was no V.T.
in the good-control group). With respect to adequate control; the
mean time of onset in the N.A.A. patients with adequate control
was 2.6 hours, and was 4 hours for the group with inadequate control,
compared with 5.7 hours and 8.6 hours for the respective placebo
groups.
For the patients treated between 5 and 12 hours from the onset
of symptoms, the mean time of onsetof V.T. was 8.2 hours in the
placebo group compared with 7.4 hours in the N.A.A. treated group.
( p = N.S.) With respect to the degree of F.F.A. control, those
patients with good F.F.A. control had a mean time of onset of 9.1 hours,
but there was no comparable placebo group. Those with poor F.F.A.
control had a mean time of onset of 4.25 hours compared with that
of 8.2 hours for the comparable placebo group.
With respect to adequate control in patients treated 5 to 12 hours
after the onset of symptoms the mean time of onset of V.T. was 8.0
hours and in the comparable placebo group was 8.2 hours. Further
subdivision was not possible because of the small numbers of patients
involved (see Table 3).
Table4.






















Number of beats in Each Episode of Ventricular Tachycardia
The number of beats in each episode of V.T. is illustrated in
Table 5. The majority of patients had ventricular tachycardia of
less than ten beats per episode and episodes of eleven beats or more
were rare. There were similar numbers of patients in both N.A.A.
and placebo treated groups who had episodes of V.T. of 4 or 5 beats
and 6-10 beats per episode.
Incidence of Ventricular Tachycardia with Short Coupling Intervals
Ventricular tachycardia of rapid overall rate and irregular coupling
intervals including those where the ventricular R wave falls close to or
on the T wave of a preceding beat has been described as a common
precursor of ventricular fibrillation. The incidence of V.T. which
included at least one coupling interval of less than 400 milliseconds
is shown in Table 6. The overall numbers of patients in the N.A.A.
and placebo treated groups having V.T. with short coupling intervals
on one or more occasions did not differ. In patients treated within
5 hours of the onset of symptoms there were fewer patients having
V.T. with short coupling intervals amongst the N.A.A. group
( 4/15 ) than in the placebo group ( 9/14 ). The incidence of this type
of V.T. appeared to be related to the degree of F.F.A. control.
The group with adequate control of F.F.A. had less of this type of
V.T. (1 /ll) than the group with inadequate control of F.F.A. (3/4)(p = 0.066)
Similarly there was less V.T. with short coupling intervals in the group
with good control of F.F.A. (0/6) than in the group with poor control of
F.F.A. ( 5/9) (p = 0.084). The group treated between 5-12 hours
from the onset of symptoms showed no difference in the incidence of
this type of V.T. when the whole N.A.A. treated group was compared
with the whole placebo group. When the degree of F.F.A. control is
considered, no differences were demonstrated between the subgroups
with the different degrees of F.F.A. control. In the placebo group,
however, there was more V.T. with short coupling intervals in the
group with the equivalent of inadequate control of F.F.A. (7 / 17)
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compared with the group with the equivalent of adequate control of
F.F.A. ( 0/3 ). There appeared therefore, to be a trend towards
a relationship between F.F .A. control and the incidence of this type
of V.T. but it did not reach statistical significance.
Plasma F.F.A. concentrations related to the Onset of Ventricular
Tachycardia
There was no significant relationship between the admission F.F.A.
concentration and the incidence of ventricular tachycardia in either
the NoA.A. treated group or the control group. ( See Table 7 )
There was no relationship between the onset of the initial episode
of V.T. and changing F.F.A. concentrations.
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No of beats in each episode of
Ventricular Tachycardia
Table 5 Number of Beats






6 4 0 1






9 8 2 2
8 ' 7 2 0









































































*Totalsreducedbyncomparedwithtabl3,fa lV.T.,bec u eE.C.Gtinadequateq lityfp rf ct analysis.
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Pre Treatment Plasma F.F.A. Concentration
F.F.A. > 1,000 juEq/L F.F.A. < 1,000 p,Eq/L
N.A.A. V.T.
13 6
34 pts. °V.T. 12 3
Placebo
V.T o 16 6
36 pts. °V.T. 10 . 4
Table 7




All patients in the N.A.A. treated group and the placebo treated
group had V.P.B.'s during the course of the recording. The highest
total V.P.B. counts were greater than 1000 per 24 hours and tended
to occur in those patients admitted earliest.
The incidence of various types of V.P.B. is demonstrated in
Tables 8- 13. The quality of the electromagnetic tape recording
was poor in one patient in the N.A.A. group and in 2 in the placebo
group, and precluded detailed analysis of the types of V.P.B. The
tables therefore refer to 33 patients treated with N.A.A. and 34
treated with placebo.
When all V.P.B. of R/T type are considered together (Table 8)
there was no significant difference in patient incidence between the
N.A.A. and placebo groups when these were compared for the whole
study, nor did sub-division into subgroups admitted between 0 and 5
hours and those admitted between 5 and 12 hours from the onset of
symptoms affect the patient incidence of all types of R/T V.P.B.
The degree of control of F.F.A. in the group admitted within 5 hours
did not influence the incidence, although in the "5 - 12 hour" group
there appeared to be more R/T V.P.B. in the group with good control
of F.F.A. when compared with the group with poor F.F.A. control
(p = N.S.) The same trend was apparent in those with adequate control
of F.F.A. compared with those with inadequate control of F.F.A
(p = N.S.) There were no significant differences between the whole
groups or any of the subgroups when the R/T phenom«anon of sinus T
waves interrupted by ventricular R waves (R/T S/V) were considered.
( See Table 9 )
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When R/T of the types where the ventricular R wave interrupted
a preceeding ventricular T wave were considered (R/T V/V), there
were no significant differences between the whole groups nor between
the subgroups admitted between 0 and 5 hours, and those admitted
between 5 and 12 hours from the onset of symptoms; (See Table 10)
Nor did the degree of F.F.A. control in the pre 5 hours group
influence the incidence of R/T V/V V.P.B. There was, however,
a significantly higher incidence of all R/T V/V V. P.B. in the 5-12
hour group where those with good control of F.F.A. were compared
with those with poor control of F.F.A. ( p = 0.032. )
The same trend was present in those with adequate control compared
with those with inadequate control. ( p = N.S. )
There was a significantly lower incidence of all R upon apex T
( R/apex T) phenomema in the pre 5 hours N.A.A. treated group
( 4/15 ) when compared with the pre 5 hours placebo treated group
( 10/14 ) ( p = 0.02) ( See Table 11 ) This difference was not
however related to the degree of F.F.A. control. The incidence of
all R/apex T phenomena was not influenced by the degree of F.F.A.
control in the patients admitted between 5 and 12 hours.
When the numbers with R/apex T of V/V type are considered
(See Table 12 ), the numbers in the N.A.A. treated group ( 2/15 )
are significantly less than those in the placebo treated group ( 8/14 )
(p = 0. 02 ). There was only one incident of R/apex T of V/V type in
each of the 2 patients in the treated group, and there were 19 incidents
in the 8 patients in the placebo treated group. No patients had R/apex
T V/V V.P.B. in the N.A.A. good control group; the 2 patients with
R/apex T V/V V.P.B. being in the group with poor control, lithe
5-12 hour group there was a trend towards a higher incidence of
R/apex T V/V V.P.B. in the group with adequate control compared
with the group with inadequate control.
The incidences of R/apex T of S/V type V.P.B. was also examined
and no significant differences were found between any of the whole
groups nor any of the subgroups. (See Table 13 )
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One patient in the N.A.A. treated group died. Death
loccurred 10 hours after starting treatment, which was commenced
7 hours from onset of symptoms. The plasma F.F. A.
concentration in this patient was 1880 jUEq/L at the start of the
study, and had fallen to 970 jUEq/L by 4 hours. No further estimates
were made before death because of the insertion of a cardiac
pacemaker and multiple therapeutic interventions.
Necropsy showed ventricular rupture.
oOo
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Serum Creatine Kinase Measurements
There was no significant difference in serum C.K.
concentrations between the N.A.A. and placebo treated groups
(Figure 15), and no significant difference in the concentrations
of C.K between the subgroups with F.F.A. good or poor,
adequate or inadequate control in either the pre or post 5-hour
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Hours from Onset of Symptoms
Figure 15. Serum Creatine Kinase in Patients treated with N.A.A.
or Placebo within 12 Hours of the Onset of Myocardial
Infarction.
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Plasma Total Catecholamines Measurements.
In every case the first sample showed a concentration greater
than the normal range. Throughout the study period no sample
showed a value in the normal range, including, therefore, the
2 patients seen within 2 hours of the onset of symptoms and the
patient not seen until 11.25 hours had elapsed.
The mean curve for the whole group, with the values related
to the time of onset of symptoms (Figure 16) shows that the mean
total plasma catecholamines concentration was consistently
elevated throughout the study period to approximately twice normal
levels. The relationship between mean plasma total catecholamines
and the incidence of ventricular tachycardia and R/T, and R/apex
T V.P. B. in both N.A.A. and placebo treated groups was examined.
There is no significant increase in the incidence of the arrhythmias
with increasing mean plasma catecholamine concentrations or with
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Figure 16. Plasma Total Catecholamines in Patients with Myocardial
Infarction Treated with N.A.A. or Placebo.
(Differences between each concentration = N.S.).
93
Blood Glucose Measurements
There was no significant difference in blood glucose
concentrations between the N.A.A., and placebo groups on
entry into the study, nor between the previously described
subgroups during the treatment period. (Table 14).
(Due to blood clots in some specimens and a problem with quality
control of the blood glucose method,results were not obtained on
all specimens submitted for analysis. Where there are deficiencies,
the number of patients contributing to each group is, therefore,
given in Table 14.)
The subgroups shown are those treated with N.A.A. within 5 hours









































There were significantly higher plasma concentrations in the
placebo group than in the N.A.A. group on entry into the study,
but this elevation did not persist into the treatment period.
During therapy there was no significant difference between the
groups and no change in plasma triglyceride concentrations
attributable to treatment with N.A.A.
Plasma Concentration of N.A.A.
Plasma 5-fluoronicotinic acid ( 5-F.N.A. ), the main
metabolite of N.A.A. was measured in all patients. The
mean plasma concentrations were significantly lower 4 hours
after starting treatment in the subgroups with poor control of
F.F.A., and during the subsequent 20 hours, when compared
with those concentrations occurring in the subgroup with good
control (p = 0.025). (Figure 17). It was clear from the individual
curves that a steadily rising plasma concentration of 5-F.N.A.
was necessary to maintain F.F.A. control. Where concentrations
of 5-FJN.A. fluctuated, or failed to increase with time, the











Figure 17. Plasma 5 - Fluoronicotinic Acid levels in Patients with
Myocardial Infarction Treated with N.A.A.
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Side-Effects of N.A.A.
In five of the 34 patients given N.A.A. there was mild
facial skin flushing. More patients vomited in the group
given N.A.A. within 5 hours of the onset of symptoms than
in the same group of placebo patients ( p= 0.05 ) Vomiting
occurred later in the group treated with N.A.A. The mean
time of onset of vomiting was 18.2 hours after starting N.A.A.
and 5.7 hours after starting placebo ( p= 0.005 ) In the N.A.A.
subgroups, vomiting started at a mean time of 17 hours in
those with good control and at a mean time of 7.8 hours in
those with poor control ( p= 0.003).
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Morphine Requirements of Patients in Trial.
Table 15 shows the distribution by treatment group of
patients requiring morphine in doses from 10 - 30 mgm or
more and those who were not given morphine either by
the G.P. or in the C.C.U.
There was no difference between the whole groups
in terms of the severity of pain as judged by the morphine
requirements. In particular there is no significant difference
in the numbers with very mild pain requiring little or no
analgesic, or in the numbers requiring the higher doses for
severe pain. The mean dose of morphine given to the N.A.A.
group was 26.2 mgm, and that given to the placebo group was
20.20 mgm. The difference is not significant. (p = N.S.)
Table 15 also shows the same assessment of morphine
requirements for the pre>-5 hours subgroups. (Good control
= 50% fall in F.F.A. and F.F.A. in normal range at 12 and
20 hours).
Again there are no significant differences between the
groups. The mean dose of morphine for the good control group
was 24.1 mgm, and that for the poor control group was 26.5 mgm.
This information supports the view that the excess of vomiting
in the N.A.A. treated group was due to the NA.A. rather than
to any difference in the quantity of other drugs given which have
major emetic side effects.
oOo
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Morphine Requirements of Whole Study Group
Omg ^ClOmg >10mg ^20mg >20mg ^30mg >30mg Total
r.A.A. 7 8 4 10 5 34
'lacebo 6 11 11 4 8 36
Morphine Requirements of Pre-5 hours N.A.A. Treated Subgroups
Omg ^10mg >10mg <C20mg >20mg ^30mg >3Omg Total
-ood Control
Subgroup
0 3 0 1 2 6
oor Control
Subgroup
2 0 0 6 2 10
Table 15
Morphine requirements of Patients with Myocardial Infarction given N.A.A.
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Blood Pressure Recordings
The blood pressure was recorded by sphygmomanometer
cuff before treatment commenced, and 4 hourly during
treatment. (See Table 16) Before treatment commenced
the mean systolic and diastolic blood pressures were
significantly lower in the N.A.A. group compared with the
placebo group. During treatment however, the pressure
in the N.A.A. group rose towards that in the placebo group
and the mean minimum systolic and diastolic pressures were
not significantly different. The mean maximum pressures
in the N.A.A. treated group, although rising during the
treatment period, never equalled the readings in the placebo
group. The N.A.A. did not therefore produce hypotension,
nor did it hold the pressure in the N.A.A. group at a
significantly lower level than that in the placebo group.
It may, however, have prevented the peak pressures in the N.A.A.
group reaching those of the placebo group, although this is













































Table16 BloodPressurerecordings(M a+S.E.M.)bef re&duri gTr atme t withNAA&PlaceboinpatientstAcu eMyo ardialInfar t on.
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Discussion.
Sudden death within the first few hours of the onset of
symptoms associated with acute myocardial infarction
accounts for the major part of the mortality from coronary
heart disease. The actual mechanism of sudden death is
not certain but, based on experience in coronary care units
and in mobile intensive care units, it seems to be due to
disturbances of cardiac rhythm, in particular ventricular
fibrillation. Arrhythmias occur principally in response
to inadequate blood flow in a coronary artery with consequent
primary, or direct, disruption of normal and fundamental
metabolic mechanisms in the myocardium.
There is a major systemic hormonal response associated
with the onset of symptoms of the acute event, with consequent
changes in plasma concentration of usual myocardial
metabolites. The presentation of abnormal patterns of
essential metabolites to the already embarrassed
myocardium represents a secondary, or indirect, disruption
of normal processes.
From experimental studies it appears that in the acutely
ischaemic myocardium there is patchy reduction in perfusion
and hence oxygenation, probably with a constantly changing
distribution of hypoxic and underperfused areas. In an under-
perfused area, F.F.A. utilisation is reduced with a
consequent rise in the local concentration. This inhibits
the utilisation of glucose and glycogen which are released
from tissue stores in response to hypoxia. In other areas
key enzyme systems cease to function due to total anoxia
and, therefore, essential ionic transport systems fail.
Local accumulation of fatty acyl CoA esters inhibit the
enzyme transport mechanisms for A.T.P. at inner mitochondrial
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membrane level and hence further endanger normal cell membrane
function.
The systemic release of catecholamines raises plasma F.F.A.
concentrations by stimulation of adipose tissue lipolysis and the
consequent increased uptake of F.F.A. by the myocardium may
further augment the local changes which have already occurred.
The local release of myocardial catecholamines may have a direct
effect on the myocardial cell membrane and decrease its stability so
encouraging spontaneous pacemaker activity. The contribution of the
systemic increase in catecholamine activity to such an effect is
undetermined.
There is abnormal glucose tolerance after myocardial infarction,
and increased glucagon secretion contributes to a rise in blood glucose.
Rises in plasma Cortisol and growth hormone output may contribute to
insulin suppression and hence altered tissue uptake of glucose.
The combined effects of high catecholamines, high F.F.A. and
reduced availability of glucose produce, therefore, local areas of
fluctuating efficiency in the maintenance of ionic pumps and of stable
impulse formation, conduction and perpetuation. The end result is
reduction in mechanical performance, and the appearance of ventricular
arrhythmias. It is not yet possible to define which, if any of the
abnormal factors is the sole or even a prime cause of the extreme
electrical instability which preceeds the onset of ventricular
fibrillation.
Che of the areas of major uncertainty is the interrelationship of
these profound biochemical changes with the known
electrophysiological events,but there is current speculation that the
relative availability of F.F.A., glucose and the inorganic ions may
be of great importance in the genesis of V.F.
The hypothesis that F.F.A. not only contribute to the adverse
metabolic balance in the hypoxic myocardium but are a major factor
in cell membrane dysfunction, has been proposed by Oliver and his
co-workers. The therapeutic implication of their observation is
m
important as the reduction of high intracellular F.F.A. concentrations
would not only diminish any direct effects they might have on enzyme
systems and the membranes, but would also reduce their inhibitory
effect on the uptake of glucose. This could produce a favourable
balance of substrates available to the myocardium during hypoxic
conditions.
The mechanism by which F.F.A. have a direct toxic effect on the
cell membrane was ascribed by Oliver to a non specific detergent effect
of F.F.A. soaps produced by F.F.A. combining with Acyl CoA and
calcium and magesium ions. More recently, however, Shug and
Shrago have confirmed the presence of Fatty Acyl CoA esters in the
mitochondria, and they also demonstrated a specific inhibitory effect
of these esters on the enzyme systems essential for the transport of
A.T.P. across the inner mitochondrial membrane. If the
intracellular concentration of F.F.A. could be reduced, therefore,
during the phase of acute hypoxia, A.T.P. might be made more
readily available, membrane function might be improved, the extent
of the infarction restricted, and the incidence of clinically detectable
arrhythmias reduced.
The Oliver hypothesis specifically relates high plasma F.F.A.
concentrations to the incidence of ventricular arrhythmias. The
investigations described in the foregoing work were specifically
designed to test this hypothesis in its clinical aspect, by showing
firstly that plasma F.F.A. concentrations could be lowered in the
acute situation in man, and secondly by observing the effects of this
manoeuvre on the incidence of ventricular arrhythmias. Of particular
importance were observations on the incidence of those arrhythmias
previously reported to have predictive value for the onset of
ventricular fibrillation.
The initial studies demonstrated that plasma F.F.A. concentrations
could be lowered in man with A.M.I, without haemodynamic effects which
might influence myocardial perfusion, and that suppression of lipolysis
could be achieved in the face of the persistent catecholamine release
which occurs in the acute stress conditions accompanying
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accompanying myocardial infarction. There was no detected
side effect attributable to the lowering of plasma F.F.A.,
although late onset nausea and vomiting occurred which was
attributed to a direct gastic irritant effect of the N.A.A.
used to inhibit lipolysis. There was no evidence of a
consistent effect of the N.A.A. on blood sugar concentrations
which might have independently altered the balance of substrates
presented to the myocardium. Nor was there any effect on plasma
total catecholamines.
In the double blind controlled study in 81 patients with
A.M.I., antilipolytic treatment with the N.A.A.
reduced elevated plasma F.F.A. concentrations to normal
levels, but the experience of the pilot studies was not
thereafter confirmed, in that the antilipolytic regimen used
was not wholly satisfactory. Only half of the patients treated
early had consistent control of plasma F.F.A., and variations
in the speed of absorption of the oral preparation of N.A.A.
during the first few hours of acute infarction may account for
this. The excess vomiting attributable to the N.A.A. may
have led to the later variability in F.F.A. control. The
analogue had to be administered every 2 hours to maintain the
plasma F.F.A. lowering effect and this may account for gastric
irritation, nausea and vomiting in some patients, as the N.A.A.
is presented as a strongly acid salt and the total dose is released
rapidly on contact of the capsule with gastric contents.
The rise in plasma concentrations of the metabolite,
5-fluoronicotinic acid, required to maintain F.F.A. control
indicates tachyphylaxis, although this may not necessarily
matter if after rapid initial control,F.F.A. need only be
consistently lowered for a relatively short period of 12-24 hours.
The rebound of plasma F.F.A. levels after withdrawal of the
N.A.A. was not associated with any adverse effects. It might
be unwise, however, to suppress elevated plasma F.F.A. levels
for a period shorter than 24 hours, since an earlier rebound
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rebound would present high plasma F.F.A. concentrations to the
myocardium at a more critical phase of ischaemia.
The changes produced by N.A.A. in plasma concentrations
of F.F.A. were not associated with a reduction in the plasma
total catecholamines. These remained at twice normal levels in
all patients for atleast 48 hours from the onset of symptoms, and
no relationship between mean or peak plasma total catecholamine
concentrations and ventricular arrhythmias could be demonstrated.
(See Appendix A)
The clearly independent lowering of plasma F.F.A. did appear
to be related to the incidence of ventricular arrhythmias, and in
assessing the success of prevention of any of the ventricular
arrhythmias, it is stressed that the criterion used for success was
that any given patient should have no episodes of that arrhythmia
during the recording period of 48 hours and not just that there should
be a reduction in the number of arrhythmic events. Furthermore,
the effect of F.F.A. suppression was considered on each individual
type of arrhythmia rather than on an undefined group of events which
might have differing origins and a differing natural incidence in
various parts of the recording period. The result of this detailed
assessment was that where N.A.A. was given during the first 5 hours
after the onset of symptoms there were fewer patients with
ventricular tachycardia, and this was related to the degree of
suppression of F.F.A. Where there was a 'good' control no patient
had V.T. and there were no episodes of V.T. with coupling intervals
of <400 msecs. Furthermore, such V.T. as did occur in the N.A.A.
treated patients with less than satisfactory control of F.F.A. was
in the earlier hours after starting treatment i.e. when F.F.A. were
coming under control but had not long been consistently in the
normal range. This is reflected in the significantly earlier mean
time of onset of V.T. in the group treated within 5 hours of the onset
of symptoms.
N.A.A. appeared to have no effect on the number of beats in the
runs of V.T. but there was a strong trend towards a reduction in
the incidence of V.T. including coupling intervals of <400msecs.
in the N.A.A. groups treated within 5 hours. This trend does not
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not reach statistical significance but is in keeping with a general
reduction in the incidence of V.T., and R/T phenomena with short
coupling intervals.
There was also a significant reduction in the number of patients
with all types of R upon apex T.V.P.B. and in particular in the
number with V.P.B. in which the R wave interrupted the apex of the T
wave of a preceding V.P.B.; this latter group being that said to
predict most reliably the subsequent onset of ventricular fibrillation.
A criticism of this interpretation of the results of the double
blind study is that the reductions in the incidence of the ventricular
arrhythmias were identified by retrospective analysis of the total
data from the study. The 0-12 hours randomisation period chosen
initially was based on earlier published reports of the natural history
of ventricular arrhythmias, The rapid natural decrease in the
incidence of ventricular tachycardia, and to a less extent of V.P.B.,
in the first 12 hours after the onset of symptoms was only revealed
after study of the control group of this trial and led to the
retrospective appraisal of the total study group. Inevitably
therefore the design of this study did not include the facility for
random allocation of patients to treatment groups at hourly intervals
of time from the onset of symptoms. During the course of this
study the results of independent studies using serial sampling of
blood in the first hours of the illness became available. These
studies revealed more rapid rates of change in the metabolic indices
than previously observed and also that the onset of major metabolic
disturbances was earlier than previously believed. The peak
elevation of plasma F.F.A. was previously thought to occur at 8
hours from the onset of symptoms, but Vetter et al, demonstrated
that it occurs at 2 hours or less from the onset of symptoms. It
might therefore be expected that if a beneficial effect were to be
obtained from lowering plasma F.F.A. concentrations it would be
most obvious in those patients treated during that period. Treatment
initiated at a later stage after the onset of symptoms might be less /
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less effective if the acutely ischaemic myocardium had already been
exposed to high levels of F.F.A. for some time. The positive
findings obtained in this study by the retrospective division of data
on a 0-5 hours and 5-12 hours basis is in keeping with these
expectations. Retrospective sub division of the data by hourly
intervals before 5 hours resulted in such small numbers in each
hourly group that formal statistical analysis was not possible and
subdivisions of the study data beyond 5 hours from the onset of symptoms
did not show significant differences between the N.A.A. and placebo
treated groups.
A further criticism of the study is again related to the 12 hour
randomisation period and the subsequent division of the data.
The difference in the mean time of admission to the trial of those
treated within 5 hours of the onset of symptoms might have accounted
for an increase in early serious ventricular arrythmias in the placebo
groups and a bias in favoyr of the N.A.A. treated group. A converse
bias might have operated in the 5-12 hour group. This cannot
however, affect the differences observed in the patient incidence
of ventricular tachycardia in relation to the degree of F„F.A. control
achieved within the N.A.A. group, since there was no difference
in the mean time of admission to the trial between the N.A.A.
treated subgroups based on the pattern of F.F.A. control.
The group with lowered plasma F.F.A. did not have lower
plasma creatine kinase levels. This might be interpreted as
suggesting that lowering of plasma . F.F. A. did not restrict the size
of the infarction as might be expected from experimental work. The
number of C.K. estimations done was insufficient to allow formal
comparison of areas below the C.K. curve (Sobel et. al. 1973) as
the initial aim of C.K. measurements in this study was to show only
that there was no gross difference in the initial size of infarction which
could bias either group.
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The extent of the unstable peri-infarction ischaemic area could
nevertheless have been minimised, and recent studies have demonstrated
that the sum of the ST segment elevations on the surface of the
myocardium is reduced where antilipolytic therapy is given in animal
experiments. Clearly, therefore, specific studies of antilipolytic
therapy in man with AMI should be undertaken when currently evolving
methods of measuring infarct size in man have been further developed.
The possibility of adverse effects of antilipolytic therapy is raised by
the higher incidence of some ventricular arrhythmias observed in some
subgroups treated with N.A.A. between 5 and 12 hours after the onset
of symptoms. The incidence of the arrhythmias does not increase in
the group given N.A.A. but it fails to fall in the manner expected if the
N.A.A. were ineffective and the pattern in the placebo group was followed.
The excess vomiting which occurred in the N.A.A. group did so at this
time, and may have prevented the gradual disappearance of the remaining
arrhythmias.
The site of action of the N.A.A. is not elucidated by this study.
The antilipolytic effect is probably on the peripheral tissues, and any
beneficial effects would be achieved by lowering circulating F.F.A. and
hence the amouit presented for uptake by the myocardium.
That there may be a local effect of N.A.A. on the myocardium is
suggested by the lack of relationship between plasma F.F.A. and the
incidence of arrhythmias in the pre 5 hours placebo subgroups with plasma
F.F.A. equivalent to "adequate control" in the treated groups. The
effects of N.A.A. could be due, therefore, to local inhibition of lipolysis
or to a primary antiarrhythmic effect of the drug unrelated to the effect of
the N.A.A. on plasma F.F.A. concentrations. These questions remain
unresolved.
The findings described in this thesis support the view that the high
plasma F.F.A. concentrations observed in man with acute myocardial
infarction represent one of the factors in the genesis of ventricular
arrhythmias in the ischaemic myocardium in man. The principal
implication of this work is that lowering plasma F.F.A. concentrations
in the earliest stages of the illness will lower the incidence of some of
these arrhythmias. Any possible reduction in the incidence of/
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of ventricular fibrillation as a consequence of this action remains
purely speculative, as consideration of the placebo group studies
indicated that whilst ventricular arrhythmias represent disturbed
myocardial function, they occur too frequently to have firm predictive
value for ventricular fibrillation in the individual patient. Nevertheless
the improvement in the balance of metabolites presented to the
myocardium achieved by lowering the plasma F.F.A. does seem to be
reflected in a decrease in the incidence of ventricular arrhythmias.
It should thereby contribute to the reversal of the adverse conditions
at cell membrane level which would, if uncorrected, allow the
appearance of ventricular fibrillation.
The maximum possible effect of antilipolytic therapy may not have
been realised by the studies described in this thesis, due to the variable
success of F.F.A. control and the limited numbers of patients studied
very early in the course of AMI to the extent that a statement about the
effect on the incidence of ventricular fibrillation could not be made.
If all the metabolic abnormalities described in the situation of
AMI contribute to cell membrane instability then correction of any one
may produce an advantageous effect, ^-blockade of the excess cate¬
cholamine secretion reduces the incidence of arrhythmias but does so
at the expense of the desirable inotropic activity of the catecholamines,
and the risk of precipitating ventricular failure is increased. Glucose
Potassium and Insulin infusions are also a logical approach to supporting
the myocardium. Glucose-insulin infusions may not only stimulate
myocardial carbohydrate metabolism but will also reduce the availability
of F.F.A. by the stimulation of F.F.A. esterification and the inhibition
of lipolysis. The infusion of large volumes of fluid at the earliest stage
of the illness is, however, impracticable and may be haemodynamically
undesirable. Attempts to use this mode of therapy have not so far
produced definite evidence of a beneficial effect. Infusion of glucose
insulin and potassium aimed specifically at lowering plasma F.F.A. to
a concentration below the established myocardial F.F.A. uptake
threshold, appears, however, to have been associated with a reduced
mortality. (Rogers, et. al. 1976)
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SUMMARY
The purpose of this thesis was four fold: the relevance of
ventricular arrhythmias to the risk of sudden death during A.M.I0
has been considered by review of the literature, and the high incidence
of ventricular arrhythmias without subsequent ventricular fibrillation
in patients with uncomplicated A.M.I, has been emphasized in the
original work that is presented. The relationship between these
arrhythmias and ventricular fibrillation has been discussed and it
has been shown to be less clear cut than previous opinions have
maintained.
The hypothesis that F.F.A. may be toxic when presented to the
ischaemic myocardium has been examined, and the experimental and
clinical evidence relevant to this hypothesis discussed.
A method of safely lowering elevated plasma F.F.A. in man with
A.M.I, has been developed and it has been applied as a test of the
hypothesis under discussion. The possible beneficial effects of
antilipolytic therapy have been suggested by a probable reduction in
the incidence of ventricular arrhythmias and the findings are supported
by work from other sources published since the studies were completed.
The short comings and advantages of this mode of treatment have been
discussed with respect to the early management of patients with acute
myocardial infarction.
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The Relevance of the Thesis to Past, Present and Future Work,
The initial observations of the relationship between raised plasma
F.F.A. and ventricular arrhythmias passed through the well known
stages of confirmation and rebuttal but, nevertheless, survived to
form the basis of the established hypothesis that F.F.A. can cause
ventricular arrhythmias. The hypothesis was tested in animal models
and supportive evidence found. It remained to return to the clinical
arena and test the hypothesis in man with acute myocardial infarction.
This thesis reports the only known attempt at this manoeuvre and is the
rational development from the earlier work. The parallel work on the
effect of F.F.A. on the size of the infarction has received
encouragement from the work of this thesis and the impressive results
obtained in reduction of the area of ischaemic damage in animal models,
will surely lead to the exploration in man of factors which will limit
infarct size.
The observation in this thesis, that any beneficial effect of
antilipolytic treatment is dependent upon its being given in the
earliest hours after the onset of symptoms associated with infarction,
gives clear guidlines about the design of future studies. These will
apply not only to further tests of the F.F.A. hypothesis but to all
attempts at prevention or minimisation of the complications of acute
myocardial infarction.
This work also supports the view that intense enquiry should
continue into the predictive value of multiple risk factors in
indentifying the individual most at risk of developing ventricular
fibrillation. It is clear that present static coronary care units
and mobile intensive care teams can make a valuable, but limited,
impression on mortality. Thus the search for a self administered
therapy which, if taken at the onset of symptoms, will prevent,
restrict or at least postpone the complications of an episode of
ischaemia must continue. The suggestion made in this thesis that an
orally administered antilipolytic therapy may not only prevent arrhythmic
complications, but may do so by favourably altering myocardial/
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myocardial metabolism, such that myocardium of doubtful
viability may also be salvaged, is a step in that direction.
Glucose, insulin and potassium therapy, ^-blockade and
antilipolytic therapy could all be reassessed at hourly intervals
from the onset of symptoms. Computer monitoring and analysis
could be utilised to detect changing patterns of arrhythmias and
used along with the newer methods of estimating infarct size to
further evaluate the modes of therapy described.
The natural history of each of the ventricular arrhythmias is
still obscure, as is their relationship with ventricular fibrillation
The natural pattern of decline in incidence of each arrhythmia may
differ for each type, and the rate of change in incidence should
clearly be taken into account in future studies. The scale of studies
needed to prove that prevention of ventricular fibrillation by any of
the suggested methods is possible is probably beyond the scope of
current research funds and facilities in this country.
Prevention of the whole syndrome of coronary disease must
remain the prime aim, but recent trends in the results of studies
directed at the correction of some of the known risk factors mitigate
against an early solution to the problem. In the meantime therefore,
it is reasonable to pursue new areas of therapeutic support for the
myocardium at the times when it seems to suffer, like the world at
large, from an energy crisis.
1H
APPENDIX A
Plasma Total-catecholamine Measurements in Placebo treated
Patients
Previous studies have related elevated levels of catecholamines in
urine and blood to the severity of infarction and to the risk of developing
ventricular arrhythmias. A relationship between raised plasma
adrenaline concentrations and ventricular arrhythmias and between
plasma nonadrenaline concentrations and the incidence of arrhythmias
has also been reported.
These earlier studies did not provide a closely spaced sequence
of measurements of plasma catecholamines or a concurrent continuous
ECG recording for identification of ventricular arrhythmias.
The placebo group of the double blind trial reported in this thesis
provides the opportunity to further consider the relationship in a
group of patients with uncomplicated myocardial infarction.
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In this placebo group of patients there was no relationship between
the incidence of ventricular tachycardia, or R-on-T VPB of any type,
and the mean or the maximum plasma total catecholamine concentrations
in patients during the first 40 hours after AMI. (See fig. i and ii)
Further there was no relationship between mean or peak catecholamine
concentrations and the incidence of R-on-apex T of S/V type, or of the
V/V type which has been said to be a precursor of ventricular
fibrillation. In some instances the patients with the highest mean
and peak plasma total catecholamine concentrations failed to show
any episode of serious ventricular arrhythmias.
Mean plasma total catecholamine concentrations for the whole
group did not fall significantly during the study and remained at
approximately twice the upper limit of the reference range
throughout the recording period (See Fig. 16). The overall incidence
of each arrhythmia however, decreased rapidly with time and although
still being observed at the end of the study the incidence had fallen
markedly by 30 hours from the onset of symptoms. At this time the
mean total-plasma-catecholamine concentrations were still at values
recorded within the first hour after the onset of symptoms.
If excess levels of plasma catecholamines are a major cause
of ventricular arrhythmias, such arrhythmias should be observed
as long as the plasma catecholamine concentration levels remain
elevated, and disappear as the catecholamine concentration eventually
declines after the acute phase of the illness. This study demonstrated
that the initial incidence of arrhythmias declines before there is any
change in plasma total catecholamine concentrations and it therefore
appears, that while high local concentrations of catecholamines
may be involved with other influences to promote the initial development
of arrhythmias, it is unlikely that the elevated plasma catecholamines
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Figure i. Relationships between mean plasma-total-catecholamine


























Figure ii. Relationship between Maximum plasma-total-catecholamine
concentrations and ventricular arrhythmias.
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APPENDIX B
The following publications were produced along with the thesis
and include work for the thesis, and work carried out at the same
time and in association with the work of the thesis.
1) Rowe, M.J.; Dolder, M.A.; Kirkby, B.J.;
Oliver, M.F. (1973) Lancet October 13th pp. 814 - 18
"The Effect of a Nicotinic Acid Analogue on Raised Plasma
F.F.A. after Acute Myocardial Infarction."
2) Rowe, M.J.; Neilson, Oliver, M.F. (1975) Lancet 1,
295 "Control of Ventricular Arrhythmias during Myocardial
Infarction using a Nicotinic Acid Analogue". (This article is
the subject of an Editorial Comment, 1975, Lancet, V. 313.)
3) Oliver, M.F.; Rowe, M.J.; Luxton, M.R.; Miller, N.E.
Neilson, J.M.M., (1976) Circulation 53, No. 3., Supp. 1, 210.
"The Effect of Reducing Circulating F.F.A. on Ventricular
Arrhythmias during Myocardial Infarction and on ST - Segment
Depression during Exercise Induced Ischaemia. "
4) Strange, R.C.; Vetter, N.J.; Rowe, M.J.; Oliver, M.F., (1974)
European Journal of Clinical Investigation 4, 115 - 119 "Plasma
cyclic A.M.P. after Acute Myocardial Infarction".
5) Strange, R.C.; Rowe, M.J.; Mjpfe, O.D.; Oliver, M.F., (1976)
Acta. Med. Scand. 199, 421.
"The Effect of Antilipolytic Agents on Cyclic A.M.P., F. F.A.
and Total Catecholamine Concentrations in Plasma".
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